[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Argon Medical Devices, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":283},{"warningLetters":4,"total":282},[5,31,53,73,96,116,137,155,174,191,208,227,245,265],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":28,"delivery_method":29,"recipient_title":20,"reference_number":20,"action_taken_date":30,"medical_device_id":20,"response_letter_date":20},3703,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026\">D&amp;H Medical Services\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>D&amp;H Medical Services\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 NW 79th Avenue, Suite 265\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@dhmedicalcenter.com\"> info@dhmedicalcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728238\u003C\u002Fp>\u003Cp>To D&amp;H Medical Services:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of D&amp;H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same ingredient as Rybelsus®”\u003C\u002Fli>\u003Cli>“Same ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nD&H Medical Services\n\n2500 NW 79th Avenue, Suite 265\n\nDoral, FL 33122\n\nUnited States\n\ninfo@dhmedicalcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728238\nTo D&H Medical Services:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of D&H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same ingredient as Ozempic®”\n“Same ingredient as Rybelsus®”\n“Same ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","D&H Medical Services","dh-medical-services-728238-06082026","2026-08-19T04:06:48.349905+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026","2026-10-26T08:08:24.115003+00:00","Warning Letter","Issued","2026-06-16","728238","Drugs","2026-08-19T04:34:50.914+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":24,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":52,"medical_device_id":20,"response_letter_date":20},350,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funomedical-device-sa-de-cv-719428-01082026\">Unomedical Device S.A. de C.V. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daihanna Peña\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Plant Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unomedical Device S.A. de C.V. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Parque Ind. Del Norte., Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Formento Ind. Lote 9, Sec. 3\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Reynosa\u003C\u002Fspan>, \u003Cspan>Tamps.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@convatec.com\"> (b)(6)@convatec.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #719428\u003C\u002Fp>\u003Cp>January 8, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Peña:\u003C\u002Fp>\u003Cp>During a Remote Regulatory Assessment of your firm located in Reynosa, Tamaulipas, Mexico from July 23, 2025 through August 8, 2025, an investigator from the United States Food and Drug Administration (FDA), reviewed the records you submitted in response to our May 22 and June 6, 2025, requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, determined that your firm manufactures insulin infusion sets for subcutaneous insulin delivery in diabetic patients. These infusion sets are sold under the Unomedical brand name and are also distributed under other brand names including, but not limited to, MiniMed Mio, MiniMed Mio 30, MiniMed Silhouette, MiniMed Sure-T, MiniMed Quick-Set, MiniMed Mio Advance, Extended Wear Infusion Set, i-port ADVANCE, and Convatec’s inset and contact detach infusion sets for use with compatible third-party insulin pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of your device are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received your responses dated August 29, 2025, September 29, 2025, and November 14, 2025 concerning our investigator's observations noted during the Remote Regulatory Assessment which were issued to your firm.\u003C\u002Fp>\u003Cp>We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) Failure to validate processes whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). For example, the water leak test method used for in-process and final inspection, complaint investigations, and for tests performed during validations and revalidations has not been validated according to your firm's own procedures, despite being critical for detecting leaks in the insulin infusion sets that could cause insulin under-delivery and diabetic ketoacidosis. Between January 2023 and June 2025, your firm has received more than 5,000 complaints related to leaking of infusion sets, where patients experienced hyperglycemia with diabetic ketoacidosis. The Work Instruction # 3806111, \"Validation of Test Methods (TMV),\" version 9.0, effective February 10, 2025, requires validation of the water leak tester to show that the test \"can consistently and accurately differentiate between the possible test states\"; however, Ms. Victoria Canela, CAPA Manager, stated that the water leak test has not been validated.\u003C\u002Fp>\u003Cp>We have reviewed your responses and conclude that they are not adequate. Your firm opened CAPA-2356512 to address this observation. Your firm provided Document No. M0666.0001, IQ\u002FOQ\u002FPQ Protocol for Validation of Test method for Leak in water Test, version 1.0. Your firm’s updated response states \"This validation has been completed and was submitted as part of our initial response,\" however, the completed validation reports were not provided. The protocol includes \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the protocol does not describe how appropriate statistical methods for data collection and analysis are used nor define the criteria for revalidation. Your firm should revise your protocol to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The revised protocol should be provided for review. When available, your firm should also provide the completed validation reports. Your firm also plans to update the Test Method Validation procedure to add test method validation for all test methods and equipment used in product release, complaint investigations, and validation\u002Frevalidation activities by October 31, 2025. The revised procedure should be provided for review.\u003C\u002Fp>\u003Cp>Finally, your firm plans to conduct a systematic review of all inspection and test equipment used for product release, complaint investigations, and validation\u002Frevalidation activities to identify any other unvalidated processes or equipment and remediate as needed by December 31, 2025. Your firm should ensure your review includes all manufacturing processes, including test methods, to ensure that any process which cannot be fully verified is validated. Your firm should provide the results of your systematic review, identifying the processes and test methods assessed and their validation status. If additional validations are needed your firm should provide a copy of the validation protocols, and if available, final reports.\u003C\u002Fp>\u003Cp>2) Failure to adequately review and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c). For example:\u003C\u002Fp>\u003Cp>a. Your firm's complaint handling procedure, Document 3709030, Complaint handling, versions 12 - 19, effective July 22, 2020 – December 18, 2024 (current) allowed the closure of over 41,000 \"Type 1\" complaints, received between June 2023 and June 2025, without investigation, because lot numbers were missing. These uninvestigated complaints included allegations of leakage, loss of physical integrity, adhesive failures, infections, and death (Complaint 2204208).\u003C\u002Fp>\u003Cp>b. In Complaint 2204208, a patient died with a blood glucose of 1.1. The customer provided the pump serial numbers, transmitter numbers, and material numbers for the reservoir and sensor, however your firm did not investigate because no lot number was provided and no attempt to collect the lot number was documented. The customer agreed to return product, but no effort to obtain the device was documented.\u003C\u002Fp>\u003Cp>We have reviewed your responses and conclude that they are not adequate. Your firm initiated CAPA-2356421 to address this observation. While your firm acknowledges procedural deficiencies and has initiated some corrective actions including reopening complaints 2204208, 1997347, and 2051281, and conducting vigilance training (Document: Infusion Care Complaint Vigilance Awareness Refresher TrainingAttendance25SEP2025.pdf), the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm’s plans do not include assessing the risk of distributed products and plans to notify or correct those distributed products which may include any user notifications, corrections, or removals of product already distributed that may be necessary to prevent a risk to health.\u003C\u002Fp>\u003Cp>We acknowledge that in your November 14, 2025 response your firm submitted revised complaint handling procedures and work instructions, however, your firm has not yet provided evidence of implementation of these corrective actions and your firm also plans to conduct a retrospective review of using its revised procedures on complaint data involving leakage, loss of physical integrity, adhesive failure, and infection, and those coded as “cannot be determined” or “no malfunction” received since June 1, 2023, and remediate as needed, by March 2026.It is unclear if this retrospective review will include all complaints involving the possible failure of the device, labeling, or packaging to meet any of its specifications. Your firm should provide a justification for the sample size selected for the retrospective review. Your firm should provide the results of the retrospective review.\u003C\u002Fp>\u003Cp>Your firm also plans to conduct a retrospective trend analysis to identify trends for each reported complaint issue by May 2026. The results of this review should be provided. Furthermore, your firm plans to conduct a retrospective review of complaints involving serious injury and\u002For death and remediate as needed by January 2026. Your firm also plans to conduct additional training regarding product specific information, complaint handling by May 2026. Your firm also plans to implement procedures to regularly audit complaint and “non-complaint” records by February 2026. The procedure and evidence of retraining should be provided for review.\u003C\u002Fp>\u003Cp>3) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>a. CAPA 1627223 was initiated on February 23, 2023 to address a trend in complaints received for leaking Inset I and Inset II infusion set products. The investigation concluded that the root cause was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, specifically involving \u003Cstrong>(b)(4)\u003C\u002Fstrong> (affecting all manufacturing lines). Corrective actions were implemented (including \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and the CAPA was closed as effective on March 14, 2025 based on a review of complaints received from 2023 and 2024 related to leaks; however, the effectiveness review was only based on a one month search of complaints and, as indicated in item two above, your firm excluded the 41,000 uninvestigated Type 1 complaints in its verification. Furthermore, the verification of effectiveness did not take into consideration whether leak failures were identified through the nonconformance process to ensure the investigation scope and root causes were adequate. Specifically, while CAPA 1627223 was in progress (Feb 2023 - Mar 2025), your firm continued to document the following seven nonconformance reports related to leak failures on Inset I and II products:\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Cthead>\u003Ctr>\u003Cth>Nonconformance Number\u003C\u002Fth>\u003Cth>Date Initiated\u003C\u002Fth>\u003Cth>Part Affected\u003C\u002Fth>\u003Cth>Description\u003C\u002Fth>\u003C\u002Ftr>\u003C\u002Fthead>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Inset: Leakage in water test Failure\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Inset: Leak failure on \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Leak on membrane in \u003Cstrong>(b)(4) \u003C\u002Fstrong>product \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Leakage in water test failure on batch \u003Cstrong>(b)(4) \u003C\u002Fstrong>Product\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure in leak test test in water \u003Cstrong>(b)(4) \u003C\u002Fstrong>Product\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure on the leak test in water.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Failure on the leak test in water.\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>b. Between December 12, 2022, and October 12, 2023, your firm received 210 complaints reporting the Varisoft infusion set tubing detached from the connector resulting in a high blood glucose level, including 86 with reported harm of hyperglycemia. However, your firm determined a CAPA was not needed even though complaints, such as 1593110 and 1619522 were categorized as severity 5 (death or life-threatening harm which requires professional medical intervention) until August 2023 (CAPA 1723998) following a supplier corrective action report due to complaints that Varisoft infusion sets have easily detached from the connector and\u002For patient line separation. This led to a Class I Recall (FDA RES 93269) initiated on October 11, 2023, more than 11 months after your firm became aware of the product defect. CAPA 1723998 concluded that the product defect was caused by a defective manufacturing machine, corrective actions were implemented, and the CAPA was closed as effective on May 5, 2025, stating “It was found 4 complaints received after the corrective action however after quality analysis on retention samples the failure was not confirmed. Therefore, it can be concluded that the CAPA was effective.” However, review of complaint data revealed approximately 180 complaints were received during the same period used for verification of effectiveness (April 2023 – August 2024), that reported Varisoft infusion set tubing detaching from the connector, including approximately 80 complaints reporting hyperglycemia. These complaints were not included in the verification check because, as indicated in item two above, your firm’s complaint handling process inadequately categorizes and investigates complaints alleging failure of the device.&nbsp;\u003C\u002Fp>\u003Cp>c. CAPA 2010953 was initiated on February 7, 2025, to address a trend of increasing complaints related to over 3,000 complaints of leaking of Extended Wear Infusion Sets (EWIS). The root cause was found to be that your firm did not conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> requirements to ensure the infusion set “stays on the patient for a usage time according to intended use after insertion”. The investigation also revealed that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. The CAPA explains there is “\u003Cstrong>(b)(4)\u003C\u002Fstrong>…It is not clear which \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, your firm failed to identify any corrective actions to address these device design deficiencies, and the only proposed corrective action is to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Additionally, CAPA 2010953 was limited to the EWIS products; however, your firm identified that all other product families also do not have \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, your firm’s Design Risk Assessment for the EWIS products, Document 3A02087 indicates that potential harm to patients \u003Cstrong>(b)(4)\u003C\u002Fstrong> as 5 (Life threatening or may result in death or disability of patient); however, your firm did not evaluate the potential impact to patients from defective products in the field.\u003C\u002Fp>\u003Cp>d. CAPA 1832980 was initiated on February 21, 2024, to address complaint handling process deficiencies including miscategorized and incorrectly coded complaints. Corrective actions, including remediating complaint records were initiated in April 2024. Complaint numbers 1997347 and 2051281 which were received based on reports of “leaking at the site.” The records document that they had been remediated as part of CAPA 1832980; however, the complaints remain incorrectly coded as: Reported Complaint Issue = “Cannot be determined” and Malfunction Code = “No malfunction based on complaint information”.\u003C\u002Fp>\u003Cp>e. CAPA 1668046 documented that the Inset Guard Ramp-Up product family failed to meet design requirements, including Product Requirement 110.14 (\"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\"), yet your firm closed this CAPA as effective in April 2025 after implementing a \"new\" test method. However, complaint data shows your firm continued to receive approximately 5,000 complaints reporting leakage of Inset Guard Ramp-Up products through June 2025, including reportable malfunctions and serious injuries, indicating that the design verification testing remains inadequate.\u003C\u002Fp>\u003Cp>We have reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-2356496 to address this observation. While your firm acknowledges CAPA deficiencies and has initiated some corrective actions including establishing \u003Cstrong>(b)(4)\u003C\u002Fstrong> starting August 27, 2025 (Documents: Meeting Minutes 27 Aug 2025, 10 Sep 2025, 24 Sep 2025), \u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP 3702002 (Corrective and Preventive Action) and related procedures, the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm's plans do not include assessing the risk of distributed products from the inadequately investigated CAPAs and any corrections or removals of product already distributed that may be necessary to prevent a risk to health.\u003C\u002Fp>\u003Cp>Your firm plans to complete reassessment of CAPAs 1627223, 2152419, and 2010953 by December 2025, with CAPA 2010953 sent back to investigation on September 22, 2025. Your firm should submit the completed CAPA investigations with verified root causes and objective evidence of effective corrective actions for review.\u003C\u002Fp>\u003Cp>Your firm also plans to conduct a retrospective review of product-related CAPAs closed since June 1, 2023, to ensure adequate verification of effectiveness and reopen as required by March 2026. However, it is unclear if this retrospective review will include assessment of distributed products that may require field action. Your firm should provide a justification for the scope and timeline of the retrospective CAPA review. Your firm should provide the results of the retrospective review.\u003C\u002Fp>\u003Cp>Your firm also plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong> by March 2026. The results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be provided. Furthermore, your firm plans to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> to monitor CAPA progress by October 2025. Your firm also plans to establish a \u003Cstrong>(b)(4)\u003C\u002Fstrong> by November 2025 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by December 2025. The revised procedures should be provided for review.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example, the information included for Complaint 1997347 reasonably suggests that four of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use, resulting in elevated blood glucose readings (hyperglycemia) that required the administration of a corrective bolus via the pump. We believe this medical intervention was necessary to prevent permanent impairment of a body function or permanent damage to a body structure. Therefore, each of these four events meets the definition of a reportable serious injury under 21 CFR 803.3. Your firm became aware of these events on September 4, 2024, but failed to submit the corresponding MDR for each of the four reportable serious injury events.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>We acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results.\u003C\u002Fp>\u003Cp>2. Failure to report the information required by § 803.52 in accordance with the requirements of §803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information for Complaint 2051281 reasonably suggests that two of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use. The serious injury MDR 3003442380-2024-05425, resulting from the same malfunction for the same device, has in the past caused or contributed to a serious injury, thereby establishing precedent that the malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for the referenced event represents a reportable malfunction under 21 CFR 803.3. Your firm became aware of these events on October 29, 2024, but failed to submit the corresponding MDR for each of the two reportable malfunction events.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>We acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these or similar violations from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrective actions will occur over time, provide a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide English translations of any documentation that is not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and we may inspect your facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm's response should be sent via email CDRHEnforcement@fda.hhs.gov. Please include in the subject line: \"CMS Case #719428\" when replying. If you have any questions about the contents of this letter, please contact Ghazaleh Esmaili at Ghazaleh.esmailit@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the observations communicated at the conclusion of the Remote Regulatory Assessment may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct them and bring your devices into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Courtney Smith\u003Cbr>U.S. Agent\u003Cbr>Courtney.smith@convatec.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDaihanna Peña\n\nRecipient Title\n\nSenior Director, Plant Operations\n\nUnomedical Device S.A. de C.V.\n\nParque Ind. Del Norte., Ave.\n\nFormento Ind. Lote 9, Sec. 3\n\nReynosa, Tamps.\n\nMexico\n\n(b)(6)@convatec.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #719428\nJanuary 8, 2026\nDear Ms. Peña:\nDuring a Remote Regulatory Assessment of your firm located in Reynosa, Tamaulipas, Mexico from July 23, 2025 through August 8, 2025, an investigator from the United States Food and Drug Administration (FDA), reviewed the records you submitted in response to our May 22 and June 6, 2025, requests for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, determined that your firm manufactures insulin infusion sets for subcutaneous insulin delivery in diabetic patients. These infusion sets are sold under the Unomedical brand name and are also distributed under other brand names including, but not limited to, MiniMed Mio, MiniMed Mio 30, MiniMed Silhouette, MiniMed Sure-T, MiniMed Quick-Set, MiniMed Mio Advance, Extended Wear Infusion Set, i-port ADVANCE, and Convatec’s inset and contact detach infusion sets for use with compatible third-party insulin pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, the manufacture, packing, storage, or installation of your device are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your responses dated August 29, 2025, September 29, 2025, and November 14, 2025 concerning our investigator's observations noted during the Remote Regulatory Assessment which were issued to your firm.\nWe address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1) Failure to validate processes whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). For example, the water leak test method used for in-process and final inspection, complaint investigations, and for tests performed during validations and revalidations has not been validated according to your firm's own procedures, despite being critical for detecting leaks in the insulin infusion sets that could cause insulin under-delivery and diabetic ketoacidosis. Between January 2023 and June 2025, your firm has received more than 5,000 complaints related to leaking of infusion sets, where patients experienced hyperglycemia with diabetic ketoacidosis. The Work Instruction # 3806111, \"Validation of Test Methods (TMV),\" version 9.0, effective February 10, 2025, requires validation of the water leak tester to show that the test \"can consistently and accurately differentiate between the possible test states\"; however, Ms. Victoria Canela, CAPA Manager, stated that the water leak test has not been validated.\nWe have reviewed your responses and conclude that they are not adequate. Your firm opened CAPA-2356512 to address this observation. Your firm provided Document No. M0666.0001, IQ\u002FOQ\u002FPQ Protocol for Validation of Test method for Leak in water Test, version 1.0. Your firm’s updated response states \"This validation has been completed and was submitted as part of our initial response,\" however, the completed validation reports were not provided. The protocol includes (b)(4). However, the protocol does not describe how appropriate statistical methods for data collection and analysis are used nor define the criteria for revalidation. Your firm should revise your protocol to include (b)(4). The revised protocol should be provided for review. When available, your firm should also provide the completed validation reports. Your firm also plans to update the Test Method Validation procedure to add test method validation for all test methods and equipment used in product release, complaint investigations, and validation\u002Frevalidation activities by October 31, 2025. The revised procedure should be provided for review.\nFinally, your firm plans to conduct a systematic review of all inspection and test equipment used for product release, complaint investigations, and validation\u002Frevalidation activities to identify any other unvalidated processes or equipment and remediate as needed by December 31, 2025. Your firm should ensure your review includes all manufacturing processes, including test methods, to ensure that any process which cannot be fully verified is validated. Your firm should provide the results of your systematic review, identifying the processes and test methods assessed and their validation status. If additional validations are needed your firm should provide a copy of the validation protocols, and if available, final reports.\n2) Failure to adequately review and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c). For example:\na. Your firm's complaint handling procedure, Document 3709030, Complaint handling, versions 12 - 19, effective July 22, 2020 – December 18, 2024 (current) allowed the closure of over 41,000 \"Type 1\" complaints, received between June 2023 and June 2025, without investigation, because lot numbers were missing. These uninvestigated complaints included allegations of leakage, loss of physical integrity, adhesive failures, infections, and death (Complaint 2204208).\nb. In Complaint 2204208, a patient died with a blood glucose of 1.1. The customer provided the pump serial numbers, transmitter numbers, and material numbers for the reservoir and sensor, however your firm did not investigate because no lot number was provided and no attempt to collect the lot number was documented. The customer agreed to return product, but no effort to obtain the device was documented.\nWe have reviewed your responses and conclude that they are not adequate. Your firm initiated CAPA-2356421 to address this observation. While your firm acknowledges procedural deficiencies and has initiated some corrective actions including reopening complaints 2204208, 1997347, and 2051281, and conducting vigilance training (Document: Infusion Care Complaint Vigilance Awareness Refresher TrainingAttendance25SEP2025.pdf), the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm’s plans do not include assessing the risk of distributed products and plans to notify or correct those distributed products which may include any user notifications, corrections, or removals of product already distributed that may be necessary to prevent a risk to health.\nWe acknowledge that in your November 14, 2025 response your firm submitted revised complaint handling procedures and work instructions, however, your firm has not yet provided evidence of implementation of these corrective actions and your firm also plans to conduct a retrospective review of using its revised procedures on complaint data involving leakage, loss of physical integrity, adhesive failure, and infection, and those coded as “cannot be determined” or “no malfunction” received since June 1, 2023, and remediate as needed, by March 2026.It is unclear if this retrospective review will include all complaints involving the possible failure of the device, labeling, or packaging to meet any of its specifications. Your firm should provide a justification for the sample size selected for the retrospective review. Your firm should provide the results of the retrospective review.\nYour firm also plans to conduct a retrospective trend analysis to identify trends for each reported complaint issue by May 2026. The results of this review should be provided. Furthermore, your firm plans to conduct a retrospective review of complaints involving serious injury and\u002For death and remediate as needed by January 2026. Your firm also plans to conduct additional training regarding product specific information, complaint handling by May 2026. Your firm also plans to implement procedures to regularly audit complaint and “non-complaint” records by February 2026. The procedure and evidence of retraining should be provided for review.\n3) Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\na. CAPA 1627223 was initiated on February 23, 2023 to address a trend in complaints received for leaking Inset I and Inset II infusion set products. The investigation concluded that the root cause was (b)(4), specifically involving (b)(4) (affecting all manufacturing lines). Corrective actions were implemented (including (b)(4)) and the CAPA was closed as effective on March 14, 2025 based on a review of complaints received from 2023 and 2024 related to leaks; however, the effectiveness review was only based on a one month search of complaints and, as indicated in item two above, your firm excluded the 41,000 uninvestigated Type 1 complaints in its verification. Furthermore, the verification of effectiveness did not take into consideration whether leak failures were identified through the nonconformance process to ensure the investigation scope and root causes were adequate. Specifically, while CAPA 1627223 was in progress (Feb 2023 - Mar 2025), your firm continued to document the following seven nonconformance reports related to leak failures on Inset I and II products:\nNonconformance NumberDate InitiatedPart AffectedDescription\n(b)(4)(b)(4)(b)(4)Inset: Leakage in water test Failure\n(b)(4)(b)(4)(b)(4)Inset: Leak failure on (b)(4)\n(b)(4)(b)(4)(b)(4)Leak on membrane in (b)(4) product (b)(4)\n(b)(4)(b)(4)(b)(4)Leakage in water test failure on batch (b)(4) Product\n(b)(4)(b)(4)(b)(4)Failure in leak test test in water (b)(4) Product\n(b)(4)(b)(4)(b)(4)Failure on the leak test in water.\n(b)(4)(b)(4)(b)(4)Failure on the leak test in water.\n\nb. Between December 12, 2022, and October 12, 2023, your firm received 210 complaints reporting the Varisoft infusion set tubing detached from the connector resulting in a high blood glucose level, including 86 with reported harm of hyperglycemia. However, your firm determined a CAPA was not needed even though complaints, such as 1593110 and 1619522 were categorized as severity 5 (death or life-threatening harm which requires professional medical intervention) until August 2023 (CAPA 1723998) following a supplier corrective action report due to complaints that Varisoft infusion sets have easily detached from the connector and\u002For patient line separation. This led to a Class I Recall (FDA RES 93269) initiated on October 11, 2023, more than 11 months after your firm became aware of the product defect. CAPA 1723998 concluded that the product defect was caused by a defective manufacturing machine, corrective actions were implemented, and the CAPA was closed as effective on May 5, 2025, stating “It was found 4 complaints received after the corrective action however after quality analysis on retention samples the failure was not confirmed. Therefore, it can be concluded that the CAPA was effective.” However, review of complaint data revealed approximately 180 complaints were received during the same period used for verification of effectiveness (April 2023 – August 2024), that reported Varisoft infusion set tubing detaching from the connector, including approximately 80 complaints reporting hyperglycemia. These complaints were not included in the verification check because, as indicated in item two above, your firm’s complaint handling process inadequately categorizes and investigates complaints alleging failure of the device.\nc. CAPA 2010953 was initiated on February 7, 2025, to address a trend of increasing complaints related to over 3,000 complaints of leaking of Extended Wear Infusion Sets (EWIS). The root cause was found to be that your firm did not conduct (b)(4) verification for the (b)(4) requirements to ensure the infusion set “stays on the patient for a usage time according to intended use after insertion”. The investigation also revealed that “(b)(4)”. The CAPA explains there is “(b)(4)…It is not clear which (b)(4)”. However, your firm failed to identify any corrective actions to address these device design deficiencies, and the only proposed corrective action is to update the (b)(4)”. Additionally, CAPA 2010953 was limited to the EWIS products; however, your firm identified that all other product families also do not have (b)(4). Furthermore, your firm’s Design Risk Assessment for the EWIS products, Document 3A02087 indicates that potential harm to patients (b)(4) as 5 (Life threatening or may result in death or disability of patient); however, your firm did not evaluate the potential impact to patients from defective products in the field.\nd. CAPA 1832980 was initiated on February 21, 2024, to address complaint handling process deficiencies including miscategorized and incorrectly coded complaints. Corrective actions, including remediating complaint records were initiated in April 2024. Complaint numbers 1997347 and 2051281 which were received based on reports of “leaking at the site.” The records document that they had been remediated as part of CAPA 1832980; however, the complaints remain incorrectly coded as: Reported Complaint Issue = “Cannot be determined” and Malfunction Code = “No malfunction based on complaint information”.\ne. CAPA 1668046 documented that the Inset Guard Ramp-Up product family failed to meet design requirements, including Product Requirement 110.14 (\"(b)(4)\"), yet your firm closed this CAPA as effective in April 2025 after implementing a \"new\" test method. However, complaint data shows your firm continued to receive approximately 5,000 complaints reporting leakage of Inset Guard Ramp-Up products through June 2025, including reportable malfunctions and serious injuries, indicating that the design verification testing remains inadequate.\nWe have reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-2356496 to address this observation. While your firm acknowledges CAPA deficiencies and has initiated some corrective actions including establishing (b)(4) starting August 27, 2025 (Documents: Meeting Minutes 27 Aug 2025, 10 Sep 2025, 24 Sep 2025), (b)(4) SOP 3702002 (Corrective and Preventive Action) and related procedures, the corrective actions are still pending. But your firm has not included a plan to address devices which do not conform to specifications which have already been distributed. Specifically, your firm's plans do not include assessing the risk of distributed products from the inadequately investigated CAPAs and any corrections or removals of product already distributed that may be necessary to prevent a risk to health.\nYour firm plans to complete reassessment of CAPAs 1627223, 2152419, and 2010953 by December 2025, with CAPA 2010953 sent back to investigation on September 22, 2025. Your firm should submit the completed CAPA investigations with verified root causes and objective evidence of effective corrective actions for review.\nYour firm also plans to conduct a retrospective review of product-related CAPAs closed since June 1, 2023, to ensure adequate verification of effectiveness and reopen as required by March 2026. However, it is unclear if this retrospective review will include assessment of distributed products that may require field action. Your firm should provide a justification for the scope and timeline of the retrospective CAPA review. Your firm should provide the results of the retrospective review.\nYour firm also plans to (b)(4) by March 2026. The results of (b)(4) should be provided. Furthermore, your firm plans to implement (b)(4) to monitor CAPA progress by October 2025. Your firm also plans to establish a (b)(4) by November 2025 and (b)(4) by December 2025. The revised procedures should be provided for review.\nMedical Device Reporting (MDR) Violations\n1. Failure to report the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example, the information included for Complaint 1997347 reasonably suggests that four of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use, resulting in elevated blood glucose readings (hyperglycemia) that required the administration of a corrective bolus via the pump. We believe this medical intervention was necessary to prevent permanent impairment of a body function or permanent damage to a body structure. Therefore, each of these four events meets the definition of a reportable serious injury under 21 CFR 803.3. Your firm became aware of these events on September 4, 2024, but failed to submit the corresponding MDR for each of the four reportable serious injury events.\nWe reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\nThe adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nWe acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results.\n2. Failure to report the information required by § 803.52 in accordance with the requirements of §803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information for Complaint 2051281 reasonably suggests that two of your firm’s AutoSoft XC infusion sets malfunctioned (i.e. device leakage) during use. The serious injury MDR 3003442380-2024-05425, resulting from the same malfunction for the same device, has in the past caused or contributed to a serious injury, thereby establishing precedent that the malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for the referenced event represents a reportable malfunction under 21 CFR 803.3. Your firm became aware of these events on October 29, 2024, but failed to submit the corresponding MDR for each of the two reportable malfunction events.\nWe reviewed your firm’s response dated August 29, 2025, and conclude that it is not adequate. In the response, your firm acknowledged the observations and stated that they have initiated a comprehensive plan to address each of the observations. However, your firm did not provide a specific plan describing how the issue will be addressed, nor did they provide a timeline for completion.\nThe adequacy of your firm’s response dated September 29, 2025, cannot be determined at this time. The response states that your firm plans to revise its complaint handling and reporting process to address the issue, complete staff training, and will conduct a retrospective review of complaints and submit any newly identified MDRs as appropriate. However, your firm has not provided documentation or evidence to demonstrate that these systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nWe acknowledge that your firm’s response dated November 14, 2025 included revised complaint handling and reporting procedures and work instructions, however, your firm has not provided evidence of implementation of these new procedures such as training and has not provided the results\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these or similar violations from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrective actions will occur over time, provide a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide English translations of any documentation that is not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and we may inspect your facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm's response should be sent via email CDRHEnforcement@fda.hhs.gov. Please include in the subject line: \"CMS Case #719428\" when replying. If you have any questions about the contents of this letter, please contact Ghazaleh Esmaili at Ghazaleh.esmailit@fda.hhs.gov.\nFinally, this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the observations communicated at the conclusion of the Remote Regulatory Assessment may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to correct them and bring your devices into compliance.\nSincerely,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nCourtney Smith\nU.S. Agent\nCourtney.smith@convatec.com","Unomedical Device S.A. de C.V.","unomedical-device-sa-de-cv-719428-01082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funomedical-device-sa-de-cv-719428-01082026","2026-10-26T08:10:17.962879+00:00","2026-02-03","719428","Medical Devices","Daihanna Peña","2026-08-19T07:16:06.283+00:00","VIA Electronic Mail","2026-01-08",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":24,"posted_date":68,"marcs_cms_no":69,"product_type":27,"closeout_date":20,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":72,"medical_device_id":20,"response_letter_date":20},2257,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","2023-01-11","647603","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":20,"letter_url":86,"updated_at":87,"action_type":23,"case_status":24,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":20,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":20,"reference_number":94,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},21927,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Biologics","Joe Spell","2026-10-27T01:19:42.766+00:00","VIA UPS and Electronic Mail","CBER 26-727246","2026-10-06",{"id":97,"raw":98,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":20,"letter_url":108,"updated_at":109,"action_type":23,"case_status":24,"posted_date":110,"marcs_cms_no":111,"product_type":90,"closeout_date":20,"issuing_office":79,"recipient_name":112,"body_fetched_at":113,"delivery_method":93,"recipient_title":20,"reference_number":114,"action_taken_date":115,"medical_device_id":20,"response_letter_date":20},543,[99,100,101,79,102,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025\">New Life Medical Services, LLC\u003C\u002Fa>","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-711102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joshua M. Mansavage\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Life Medical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>244 Crystal Grove Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lutz\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33548-6460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Joshm@newliferegen.com\"> Joshm@newliferegen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 24, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25- 711102\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Mansavage:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\u003C\u002Fli>\u003Cli>Your Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\u003C\u002Fli>\u003Cli>Your training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\u003C\u002Fli>\u003Cli>Your package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\u003C\u002Fli>\u003Cli>Your Physician Guide states:\u003Cbr>o “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\u003Cbr>o Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\u003C\u002Fli>\u003Cli>Your product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\u003C\u002Fli>\u003Cli>Your website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\u003C\u002Fli>\u003Cli>One of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have concerns about the following products:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&amp;C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\u003C\u002Fli>\u003Cli>We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-711102\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoshua M. Mansavage\n\nRecipient Title\n\nChief Executive Officer\n\nNew Life Medical Services, LLC\n\n244 Crystal Grove Blvd\n\nLutz, FL 33548-6460\n\nUnited States\n\nJoshm@newliferegen.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 24, 2025\nCBER 25- 711102\nDear Mr. Mansavage:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+1, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes2), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\nYour Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\nYour training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\nYour package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\nYour Physician Guide states:\no “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\no Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\nYour product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\nYour website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\nOne of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\nIn addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nAdditional Concerns\nIn addition to the violations described above, we have concerns about the following products:\nFDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge4. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\nWe also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\n2 You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\n3 Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\n4 Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”","New Life Medical Services, LLC","new-life-medical-services-llc-711102-09242025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025","2026-10-26T08:09:32.410522+00:00","2025-10-07","711102","Joshua M. Mansavage","2026-08-19T16:15:04.082+00:00","CBER 25-711102","2025-09-24",{"id":117,"raw":118,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":128,"fei_number":20,"letter_url":129,"updated_at":130,"action_type":23,"case_status":24,"posted_date":131,"marcs_cms_no":132,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":20,"reference_number":20,"action_taken_date":136,"medical_device_id":20,"response_letter_date":20},1152,[119,120,121,37,122,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-11T04:00:00Z\">10\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024\">Adept Medical Ltd. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Murray Fenton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder, CEO and Guiding Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Medical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-6 Mc Donald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morningside\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Auckland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fenton:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\u003C\u002Fp>\n\n\u003Cp>2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Biological Indicator is an off the shelf product from supplier where \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\u003C\u002Fli>\n\t\u003Cli>The BI is packaged in a foil pouch designed to protect the product from humidity excursions.\u003C\u002Fli>\n\t\u003Cli>The potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine whether sterility was compromised.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's ultrasonic cleaning process using the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is not adequately validated according to your firm's Manufacturing Process&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\u003C\u002Fp>\n\n\u003Cp>2) During the inspection, your firm stated that it had not validated the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>process for the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm&nbsp;stated that the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp; Adept Medical also confirmed during the inspection that&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;had not validated the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and that prior to Spring 2023,&nbsp;\u003Cstrong>(b)(4) \u003C\u002Fstrong>the\u003Cstrong>&nbsp;\u003C\u002Fstrong>NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>who also did not have a&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> NeoZoline Ventilation Tube.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is an existing validated sterilization process indicating a sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Annual bioburden results of pre-cleaned devices have bioburden levels below&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU.\u003C\u002Fli>\n\t\u003Cli>Current validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm has not provided any evidence to substantiate your claims that the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>sterility assurance level or the bioburden limits below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\u003C\u002Fp>\n\n\u003Cp>1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>The FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The NC records did not adequately document the evaluation of the identified nonconformities.\u003C\u002Fli>\n\t\u003Cli>The rationale for not conducting related investigations was inadequately documented in all six NC records.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm explained that incoming NeoZoline Ventilation Tubes \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>are not inspected upon arrival.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Your firm further stated that they \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>This target achievement was cited as the reason for not taking further action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\u003C\u002Fp>\n\n\u003Cp>5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm was asked whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the NeoZoline ventilation tubes was validated&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated you have no knowledge or documentation regarding&nbsp;whether the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for the NeoZoline Ventilation Tubes had been properly&nbsp;validated.&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical learned the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;units of NeoZoline Ventilation Tubes in various types from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between June 2023 and November 2023. They released \u003Cstrong>(b)(4) \u003C\u002Fstrong>units\u003Cstrong>&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;&nbsp;\u003C\u002Fstrong>Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>indicated no adverse events.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Post market surveillance data indicated we have had no product safety or performance complaints since product launch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;the NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>did not have any documentation that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>device was validated.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Any \u003Cstrong>(b)(4)\u003C\u002Fstrong> may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that it can be properly sterilized without&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> becoming unsafe. The change in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Registrar Corp.,\u003Cbr>\n144 Research Drive,\u003Cbr>\nHampton, Virginia,\u003Cbr>\nUSA 23666\u003Cbr>\nPhone: Tel: 1-757-224-0177, Ext.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nEmail:\u003Cstrong>(b)(4)\u003C\u002Fstrong>@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Murray Fenton\n\nRecipient Title\n\nFounder, CEO and Guiding Director\n\nAdept Medical Ltd.\n\n2-6 Mc Donald Street\n\nMorningside\n\nAuckland\n\nNew Zealand\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nOctober 11, 2024\n\nDear Mr. Fenton:\n\nDuring an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\n\nFor example:\n\n1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator (b)(4) (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by (b)(4) with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or (b)(4) Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the (b)(4) Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\n\n2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. (b)(4). Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties. (b)(4)\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\n\nThe (b)(4) Biological Indicator is an off the shelf product from supplier where (b)(4) has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\n\nThe BI is packaged in a foil pouch designed to protect the product from humidity excursions.\n\nThe potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\n\nAdditionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\n\n(b)(4)\n\nBased on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. (b)(4) your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\n\nAdditionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator (b)(4) to determine whether sterility was compromised.\n\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\n\n1) Your firm's ultrasonic cleaning process using the (b)(4) Cleaner (b)(4) is not adequately validated according to your firm's Manufacturing Process (b)(4). During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\n\n2) During the inspection, your firm stated that it had not validated the (b)(4) process for the NeoZoline Ventilation Tube (b)(4). Your firm stated that the (b)(4). Adept Medical also confirmed during the inspection that (b)(4) had not validated the NeoZoline Ventilation Tube (b)(4) and that prior to Spring 2023, (b)(4) the NeoZoline Ventilation Tube (b)(4) who also did not have a (b)(4) NeoZoline Ventilation Tube.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\n\nThere is an existing validated sterilization process indicating a sterility assurance level of (b)(4)\n\nAnnual bioburden results of pre-cleaned devices have bioburden levels below (b)(4) CFU.\n\nCurrent validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm has not provided any evidence to substantiate your claims that the (b)(4) sterility assurance level or the bioburden limits below (b)(4) CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the (b)(4) Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\n\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\n\nYour firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\n\n1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\n\n2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\n\n3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure (b)(4) the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure (b)(4)\n\nYour firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\n\nThe FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\n\nThe NC records did not adequately document the evaluation of the identified nonconformities.\n\nThe rationale for not conducting related investigations was inadequately documented in all six NC records.\n\nYour firm explained that incoming NeoZoline Ventilation Tubes (b)(4) are not inspected upon arrival. (b)(4). Your firm further stated that they (b)(4). This target achievement was cited as the reason for not taking further action.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\n\nAdditionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\n\n5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\n\nDuring the inspection, your firm was asked whether the (b)(4) for the NeoZoline ventilation tubes was validated (b)(4). Your firm stated you have no knowledge or documentation regarding whether the (b)(4) for the NeoZoline Ventilation Tubes had been properly validated. (b)(4) Adept Medical learned the (b)(4) Adept Medical received (b)(4) units of NeoZoline Ventilation Tubes in various types from (b)(4) between June 2023 and November 2023. They released (b)(4) units ((b)(4) boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were (b)(4). Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\n\nThe post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by (b)(4) indicated no adverse events.\n\n(b)(4)\n\nPost market surveillance data indicated we have had no product safety or performance complaints since product launch.\n\nHowever, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier (b)(4) the NeoZoline Ventilation Tube (b)(4) did not have any documentation that the (b)(4) device was validated.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\n\nOur inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\n\nSpecifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a (b)(4) which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if (b)(4). Any (b)(4) may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the (b)(4) to ensure that it can be properly sterilized without (b)(4) becoming unsafe. The change in (b)(4) may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the (b)(4) modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\n(b)(4), Registrar Corp.,\n\n144 Research Drive,\n\nHampton, Virginia,\n\nUSA 23666\n\nPhone: Tel: 1-757-224-0177, Ext. (b)(4)\n\nEmail:(b)(4)@registrarcorp.com","Adept Medical Ltd.","adept-medical-ltd-692226-10112024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024","2026-10-26T08:07:50.120298+00:00","2024-11-26","692226","Mr. Murray Fenton","2026-08-19T17:57:49.713+00:00","Via Email","2024-10-11",{"id":138,"raw":139,"subject":143,"body_html":144,"body_text":145,"firm_name":146,"letter_id":147,"created_at":128,"fei_number":20,"letter_url":148,"updated_at":149,"action_type":23,"case_status":24,"posted_date":150,"marcs_cms_no":151,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":152,"body_fetched_at":153,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":154,"medical_device_id":20,"response_letter_date":20},1030,[140,141,142,37,143,13,13,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-05T05:00:00Z\">02\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqapel-medical-inc-699244-02052025\">Q’Apel Medical, Inc.\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jodie C. Fam\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Q’Apel Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4245 Technology Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fremont\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94538\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 5, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Fam:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Fremont, CA on July 29, 2024, through August 8, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the 072 Aspiration System (also marketed under the trade name “HIPPO”). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed information collected during the inspection of your firm located in Fremont, California on July 29, 2024, through August 8, 2024, and determined that the 072 Aspiration System (HIPPO) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C.\u003C\u002Fp>\u003Cp>Specifically, FDA cleared, under K222786, the device that you identified in your submission to the agency as the 072 Aspiration System with the following indications, “072 Aspiration Catheter: As part of the 072 Aspiration System, the 072 Aspiration Catheter with a compatible suction pump is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. Aspiration Tubing: As part of the 072 Aspiration System, the Aspiration Tubing is intended to connect the 072 Aspiration Catheter to a compatible suction pump.” The 072 Aspiration System that was presented to us was cleared under K222786 with a design that included a catheter shaft with an inner diameter of 0.072 inch and an outer diameter of 0.0855 inch for the entire catheter working length. The submission that we numbered K222786 did not describe technological characteristics of the distal nitinol tip that would enable expansion of the distal tip to larger diameters or compression of the distal tip during clinical use. However, your firm’s promotion of the device and information collected during the inspection provides evidence that the device as it was designed and developed but not described in your submission includes a nitinol tip with technological characteristics that allow for expansion in diameter and compression in length, i.e., a device for which your firm lacks clearance or approval. Examples of the promotion and information include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> data report of tip compression testing (“Hippo Tip Vacuum Ball Testing”) was shared via emails exchanged within Q’Apel Medical \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The data include tip diameter and length measurements of multiple catheter tips (“bad units” and “good units”) while vacuum was applied to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball with a diameter larger than the HIPPO distal tip diameter. Multiple images show increased diameters of the distal region of the nitinol tip expanding around the surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball with reported increases in diameters of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “good units” and increases in diameter of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “bad units.” The \u003Cstrong>(b)(4)\u003C\u002Fstrong> data reports tip diameters ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch with aspiration applied to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ball, compared to the relaxed tip diameter of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch to \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> data reports accompanying changes in tip length of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (relaxed tip lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch, compressed under ball aspiration to lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch) for “good units” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (relaxed tip lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch, compressed under ball aspiration to lengths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> inch) for “bad units.” The distinction of “good units” and “bad units” is not described in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> data. However, both “good units” and “bad units” describe evidence of increased HIPPO distal tip diameters and compressed tip lengths when aspiration was applied to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> balls. The submission K222786 did not provide images or information to show expansion of the distal tantalum markers or compression of tip length of the nitinol tip as shown in the images included in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> data of tip compression testing (“Hippo Tip Vacuum Ball Testing”).\u003C\u002Fli>\u003Cli>The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes a video on page 35 of 45 titled “Mechanism of action,” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. The video shows the catheter tip compress near the mid-point of the nitinol tip structure (with possible increased diameter), while the distal tantalum petal markers are obscured by the simulated clot. A second distinct slow-motion video also titled, “Mechanism of action,” is included on page 36 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. This video shows the HIPPO catheter tip prior to contact with the simulated clot and upon contact with the simulated clot, the distal tantalum petal markers on the most distal struts of the nitinol tip are shown to flare at the edges combined with longitudinal compression of the nitinol tip while aspiration is applied to the clot until the clot is fully ingested through the catheter lumen. Page 37 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes a slow-motion video titled, “Mechanism of action: RED 72,” that shows aspiration of simulated clot with the cleared RED 72 Reperfusion Catheter (K211654) that was cited as a reference device during review of K222786 for the 072 Aspiration System (HIPPO). The video of the RED 72 Reperfusion Catheter does not show compression of the catheter tip or expansion of the distal catheter tip as observed in the videos of the HIPPO device on pages 35 and 36 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Page 45 of 45 of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” also includes a claim that the HIPPO provides “insightful navigation from a tip that flexes to any clot morphology.” The submission K222786 of the 072 Aspiration System (HIPPO) did not provide images that showed compression of the nitinol tip nor flaring of the distal petals of the nitinol tip as shown in videos presented in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>• Drawing CS00788, “072 Catheter Nitinol Tip,” descriptions in the “Design History” notes that revision E updates included, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The version of the drawing provided in K222786\u002FS001, Appendix 27, was revision D and did not include descriptions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification changes or “\u003Cstrong>(b)(4)\u003C\u002Fstrong> compression testing with tip compression tool.” The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, CS 00788 Catheter Nitinol Tip,” document number QI 01560 describes \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The images and test methods for compression of the nitinol tip were not described in drawing CS00788, revision D, provided in K222786. The submission K222786 otherwise did not provide images that showed compression of the nitinol tip as described in document QI 01560.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During review of K222786, FDA asked for a description of the principle of operation and mechanism of action of the 072 Aspiration Catheter distal tip, including the tip dimensions related to the dimensions of the remainder of the catheter shaft, in the Refuse-to-Accept (RTA) notification dated September 30, 2022. The response provided in the document “002_Cover Letter_RTA_Final.pdf” of the K222786\u002FS001 submission dated October 24, 2022, stated that the 072 Aspiration Catheter tip had “\u003Cem>the same Internal (0.072”) and External (0.0855”) dimensions (ID, OD) as the rest of the catheter’s usable length. The length of the tip is \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. The flexible tip is a passive structure that does not have an active mechanism of action and is not self-expanding\u003C\u002Fem>.” The information gathered in the inspection conducted July 29, 2024, through August 8, 2024, at your firm raises concerns that the information provided to FDA for review in K222786 did not accurately disclose the technological characteristics of the nitinol tip and the changes in diameter and length of the distal tip that could be exhibited during use conditions for aspiration of thrombus from patients experiencing acute ischemic stroke. These different technological characteristics of the nitinol tip to change in length and diameter constitute a change or modification in the device that could significantly affect the safety or effectiveness of the device (e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process) (21 CFR 807.81(a)(3)).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the FDA. See 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that Q’Apel Medical cease any activities that result in the misbranding or adulteration of the 072 Aspiration System (HIPPO), such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received response from Jim Talbot, Vice President Regulatory, Quality, and Clinical Affairs dated August 28, 2024, September 26, 2024, and November 27, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately document design input requirements as required by 21 CFR 820.30(c).\u003C\u002Fp>\u003Cp>For example, your firm did not adequately define the physical, performance, and other design requirements for design inputs to include tip compression, aspiration\u002Fsuction pump, tip deflection, and treatment location for your firm’s 072 Aspiration System (Hippo), which are identified in your documents titled, Product Specification 072 Aspiration System (PS 00922, Rev. G) and Customer Requirement Specification Form (CRS 00848, Rev. D).\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm has not adequately defined specifications for tip elongation and compression (PS-11.5.2), aspiration flow rate (PS-11.5.3) and tip deflection (PS-11.5.9) that are identified in your document titled, Product Specification, PS 00922, Revision H.\u003C\u002Fp>\u003Cp>Your firm provided the document titled, Draft Research Report, Aspiration System, Aspiration Flowrate Acceptance Criteria, RR 02139, in your response dated August 28, 2024. This document appears to leverage previous testing of the Aspiration flowrate to define measurable acceptance criteria for future Aspiration Flowrate testing. The comparative device testing was conducted on a sample size of three \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The conclusion states an acceptance interval for the average flow rate is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This value was not reflected in your Product Specification documentation or the Test Protocol, TP 00927, which is to be executed for future verification testing by a third-party service provider. It is not clear what this data will be used for.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design inputs and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for design verification as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>For example, your firm did not adequately define acceptance criteria that can be verified for Aspiration Flowrate, Tip Deflection, and Tip Compression and Elongation in your protocol titled, Test Protocol, Device Performance Design Verification Validation, FG 00806, FG 00995 (TP 00927, Rev. C).\u003C\u002Fp>\u003Cp>Additionally, the verification test performed for Aspiration Flowrate and documented in Test Report 072 Aspiration System, Design Verification Validation, FG00806, FG 00995, Aspiration Flowrate (TR 00927-15, Rev. A), was conducted using \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum setting, whereas the Instructions for Use for the device describes \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum settings the device can be used with. There is no documented rationale to justify why testing flowrate at \u003Cstrong>(b)(4)\u003C\u002Fstrong> setting is adequate.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm still has not implemented your design control procedure, in that your design verification protocol continues to not establish acceptance criteria for specifications to include tip deflection, elongation and compression, and aspiration flow rate that can be verified. Additionally, your firm’s rationale for testing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> vacuum pressure is inadequate. Verification testing should be performed for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> ranges utilized by the device.\u003C\u002Fp>\u003Cp>Your firm stated that you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the Test Report has not been provided to FDA.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design verification and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for design change as required by 21 CFR 820.30(i).\u003C\u002Fp>\u003Cp>For example, your firm has not implemented your procedure for design changes titled, Design Control (SOP 00003, Rev. C, effective date 02\u002F01\u002F2021 &amp; Rev. D, effective date 11\u002F14\u002F2022) (revisions in effect when design changes were processed), which states that design changes are subject to original verification or validation tests and if no test(s) or a subset is planned, a justification is required. Specifically, your firm has not evaluated the impact changes may have to original verification or validation tests or provided a justification if no test(s) or a subset is required. Design changes were made to update the specification for your 072 Cather, Nitinol Tip \u003Cstrong>(b)(4)\u003C\u002Fstrong> (under ECO 1142) and to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification (under ECO 1360) \u003Cstrong>(b)(4)\u003C\u002Fstrong> acceptability range \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No assessment was documented of the potential impact the changes could have on completed verification and\u002For validation tests.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s reevaluation of ECO 1360 states that the firm’s risk management document, RM 00951, Design FMEA, 072 Aspiration System, was updated in ECO 1300 to capture the new risk identified with SA 00570 \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It further states that testing was performed via \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm determined that verification and\u002For validation testing was not required. This assessment is inadequate. Testing should be documented and performed according to a defined protocol.\u003C\u002Fp>\u003Cp>Please evaluate the adequacy of your corrective actions related to design changes and continue to provide us information related to your ongoing corrective actions.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>For example, your firm has not adequately implemented your complaint procedure, Complaint Handling and Customer Feedback (SOP 00148, Rev. M, effective date 02\u002F27\u002F2024), which requires returned product analysis to be completed within 30 days after receiving the product from the field. Specifically,\u003C\u002Fp>\u003Cul>\u003Cli>CN 0251 was opened to document a complaint reporting resistance was felt while the Hippo 072 Aspiration Catheter was inside an access catheter. The associated complaint product was received by your firm on 06\u002F12\u002F2024 under RMA0494 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\u003C\u002Fli>\u003Cli>CN 0252 was opened to document a complaint reporting stretching on the distal portion of the 072 Aspiration Tubing. The associated complaint product was received by your firm on 06\u002F27\u002F2024 under RMA0493 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Removing the 30-day timeframe for completing the returned product analysis may impact your firm’s assessment of complaints that are determined to be malfunctions and thus your firm’s adherence to reporting timeframes required as part of the Medical Device Reporting (MDR) Regulation (see 21 CFR Part 803). Your firm should provide a risk-based justification for the removal of the requirement and evaluate complaints to determine if any unreported MDRs were found.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish and maintain procedures for document control as required by 21 CFR 820.40.\u003C\u002Fp>\u003Cp>For example, your firm did not adequately implement your document control procedures as outlined in \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SOP 00002, Rev. R, effective date 05\u002F24\u002F2024 (current revision), Rev. P, effective date 02\u002F02\u002F2024, and Rev. N, effective date 07\u002F14\u002F2023. Section 6.1 of your procedure titled \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SOP 00460, Rev, A, effective date 9\u002F14\u002F2020) \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, the following promotional material for the 072 Aspiration System (Hippo) was not developed and approved per the firm’s document control procedures:\u003C\u002Fp>\u003Cul>\u003Cli>A video clip depicting the tip of the Hippo aspiration catheter flaring out\u003C\u002Fli>\u003Cli>A video clip referring the to the Hippo aspiration catheter tip as adaptive, depicting the tip of the Hippo aspiration catheter flaring out, and referencing R&amp;D Aspiration Grip Force data\u003C\u002Fli>\u003Cli>A press release announcing the clearance of the Hippo 072 Aspiration System that describes the aspiration tip as adaptive\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s response and cannot determine the adequacy at this time. Your firm extended the target completion date to 11\u002F25\u002F2025, for compiling of a list of marketing\u002F promotional content for their Armadillo and Walrus devices and evaluating if product claims were found. \u003Cstrong>(b)(4)\u003C\u002Fstrong>; therefore, we request that you continue to provide information related to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via e-mail to: Jessica Mu, Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Refer to the Unique Identification Number, \u003Cstrong>CMS # 699244\u003C\u002Fstrong>, when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov or 619-941-3763.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJodie C. Fam\n\nRecipient Title\n\nChief Executive Officer\n\nQ’Apel Medical, Inc.\n\n4245 Technology Drive\n\nFremont, CA 94538\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nFebruary 5, 2025\nDear Ms. Fam:\nDuring an inspection of your firm located in Fremont, CA on July 29, 2024, through August 8, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the 072 Aspiration System (also marketed under the trade name “HIPPO”). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed information collected during the inspection of your firm located in Fremont, California on July 29, 2024, through August 8, 2024, and determined that the 072 Aspiration System (HIPPO) is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C.\nSpecifically, FDA cleared, under K222786, the device that you identified in your submission to the agency as the 072 Aspiration System with the following indications, “072 Aspiration Catheter: As part of the 072 Aspiration System, the 072 Aspiration Catheter with a compatible suction pump is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. Aspiration Tubing: As part of the 072 Aspiration System, the Aspiration Tubing is intended to connect the 072 Aspiration Catheter to a compatible suction pump.” The 072 Aspiration System that was presented to us was cleared under K222786 with a design that included a catheter shaft with an inner diameter of 0.072 inch and an outer diameter of 0.0855 inch for the entire catheter working length. The submission that we numbered K222786 did not describe technological characteristics of the distal nitinol tip that would enable expansion of the distal tip to larger diameters or compression of the distal tip during clinical use. However, your firm’s promotion of the device and information collected during the inspection provides evidence that the device as it was designed and developed but not described in your submission includes a nitinol tip with technological characteristics that allow for expansion in diameter and compression in length, i.e., a device for which your firm lacks clearance or approval. Examples of the promotion and information include:\n(b)(4) data report of tip compression testing (“Hippo Tip Vacuum Ball Testing”) was shared via emails exchanged within Q’Apel Medical (b)(4). The data include tip diameter and length measurements of multiple catheter tips (“bad units” and “good units”) while vacuum was applied to a (b)(4) ball with a diameter larger than the HIPPO distal tip diameter. Multiple images show increased diameters of the distal region of the nitinol tip expanding around the surface of the (b)(4) ball with reported increases in diameters of (b)(4) for “good units” and increases in diameter of (b)(4) for “bad units.” The (b)(4) data reports tip diameters ranging from (b)(4) inch with aspiration applied to the (b)(4) ball, compared to the relaxed tip diameter of (b)(4) inch to (b)(4) inch. The (b)(4) data reports accompanying changes in tip length of (b)(4) (relaxed tip lengths of (b)(4) inch, compressed under ball aspiration to lengths of (b)(4) inch) for “good units” and (b)(4) (relaxed tip lengths of (b)(4) inch, compressed under ball aspiration to lengths of (b)(4) inch) for “bad units.” The distinction of “good units” and “bad units” is not described in the (b)(4) data. However, both “good units” and “bad units” describe evidence of increased HIPPO distal tip diameters and compressed tip lengths when aspiration was applied to the (b)(4) balls. The submission K222786 did not provide images or information to show expansion of the distal tantalum markers or compression of tip length of the nitinol tip as shown in the images included in the (b)(4) data of tip compression testing (“Hippo Tip Vacuum Ball Testing”).\nThe “(b)(4)” includes a video on page 35 of 45 titled “Mechanism of action,” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. The video shows the catheter tip compress near the mid-point of the nitinol tip structure (with possible increased diameter), while the distal tantalum petal markers are obscured by the simulated clot. A second distinct slow-motion video also titled, “Mechanism of action,” is included on page 36 of 45 of the “(b)(4)” that shows the nitinol tip of the HIPPO catheter aspirating a simulated clot. This video shows the HIPPO catheter tip prior to contact with the simulated clot and upon contact with the simulated clot, the distal tantalum petal markers on the most distal struts of the nitinol tip are shown to flare at the edges combined with longitudinal compression of the nitinol tip while aspiration is applied to the clot until the clot is fully ingested through the catheter lumen. Page 37 of 45 of the “(b)(4)” includes a slow-motion video titled, “Mechanism of action: RED 72,” that shows aspiration of simulated clot with the cleared RED 72 Reperfusion Catheter (K211654) that was cited as a reference device during review of K222786 for the 072 Aspiration System (HIPPO). The video of the RED 72 Reperfusion Catheter does not show compression of the catheter tip or expansion of the distal catheter tip as observed in the videos of the HIPPO device on pages 35 and 36 of 45 of the “(b)(4).” Page 45 of 45 of the “(b)(4)” also includes a claim that the HIPPO provides “insightful navigation from a tip that flexes to any clot morphology.” The submission K222786 of the 072 Aspiration System (HIPPO) did not provide images that showed compression of the nitinol tip nor flaring of the distal petals of the nitinol tip as shown in videos presented in the “(b)(4).”\n• Drawing CS00788, “072 Catheter Nitinol Tip,” descriptions in the “Design History” notes that revision E updates included, “(b)(4).” The version of the drawing provided in K222786\u002FS001, Appendix 27, was revision D and did not include descriptions of (b)(4) specification changes or “(b)(4) compression testing with tip compression tool.” The “(b)(4), CS 00788 Catheter Nitinol Tip,” document number QI 01560 describes (b)(4). The images and test methods for compression of the nitinol tip were not described in drawing CS00788, revision D, provided in K222786. The submission K222786 otherwise did not provide images that showed compression of the nitinol tip as described in document QI 01560.\nDuring review of K222786, FDA asked for a description of the principle of operation and mechanism of action of the 072 Aspiration Catheter distal tip, including the tip dimensions related to the dimensions of the remainder of the catheter shaft, in the Refuse-to-Accept (RTA) notification dated September 30, 2022. The response provided in the document “002_Cover Letter_RTA_Final.pdf” of the K222786\u002FS001 submission dated October 24, 2022, stated that the 072 Aspiration Catheter tip had “the same Internal (0.072”) and External (0.0855”) dimensions (ID, OD) as the rest of the catheter’s usable length. The length of the tip is (b)(4)”. The flexible tip is a passive structure that does not have an active mechanism of action and is not self-expanding.” The information gathered in the inspection conducted July 29, 2024, through August 8, 2024, at your firm raises concerns that the information provided to FDA for review in K222786 did not accurately disclose the technological characteristics of the nitinol tip and the changes in diameter and length of the distal tip that could be exhibited during use conditions for aspiration of thrombus from patients experiencing acute ischemic stroke. These different technological characteristics of the nitinol tip to change in length and diameter constitute a change or modification in the device that could significantly affect the safety or effectiveness of the device (e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process) (21 CFR 807.81(a)(3)).\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the FDA. See 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that Q’Apel Medical cease any activities that result in the misbranding or adulteration of the 072 Aspiration System (HIPPO), such as the commercial distribution of the device for the uses discussed above.\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received response from Jim Talbot, Vice President Regulatory, Quality, and Clinical Affairs dated August 28, 2024, September 26, 2024, and November 27, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately document design input requirements as required by 21 CFR 820.30(c).\nFor example, your firm did not adequately define the physical, performance, and other design requirements for design inputs to include tip compression, aspiration\u002Fsuction pump, tip deflection, and treatment location for your firm’s 072 Aspiration System (Hippo), which are identified in your documents titled, Product Specification 072 Aspiration System (PS 00922, Rev. G) and Customer Requirement Specification Form (CRS 00848, Rev. D).\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm has not adequately defined specifications for tip elongation and compression (PS-11.5.2), aspiration flow rate (PS-11.5.3) and tip deflection (PS-11.5.9) that are identified in your document titled, Product Specification, PS 00922, Revision H.\nYour firm provided the document titled, Draft Research Report, Aspiration System, Aspiration Flowrate Acceptance Criteria, RR 02139, in your response dated August 28, 2024. This document appears to leverage previous testing of the Aspiration flowrate to define measurable acceptance criteria for future Aspiration Flowrate testing. The comparative device testing was conducted on a sample size of three (b)(4). The conclusion states an acceptance interval for the average flow rate is (b)(4). This value was not reflected in your Product Specification documentation or the Test Protocol, TP 00927, which is to be executed for future verification testing by a third-party service provider. It is not clear what this data will be used for.\nPlease evaluate the adequacy of your corrective actions related to design inputs and continue to provide us information related to your ongoing corrective actions.\n2. Failure to adequately establish and maintain procedures for design verification as required by 21 CFR 820.30(f).\nFor example, your firm did not adequately define acceptance criteria that can be verified for Aspiration Flowrate, Tip Deflection, and Tip Compression and Elongation in your protocol titled, Test Protocol, Device Performance Design Verification Validation, FG 00806, FG 00995 (TP 00927, Rev. C).\nAdditionally, the verification test performed for Aspiration Flowrate and documented in Test Report 072 Aspiration System, Design Verification Validation, FG00806, FG 00995, Aspiration Flowrate (TR 00927-15, Rev. A), was conducted using (b)(4) vacuum setting, whereas the Instructions for Use for the device describes (b)(4) vacuum settings the device can be used with. There is no documented rationale to justify why testing flowrate at (b)(4) setting is adequate.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm still has not implemented your design control procedure, in that your design verification protocol continues to not establish acceptance criteria for specifications to include tip deflection, elongation and compression, and aspiration flow rate that can be verified. Additionally, your firm’s rationale for testing a (b)(4) vacuum pressure is inadequate. Verification testing should be performed for all (b)(4) ranges utilized by the device.\nYour firm stated that you are (b)(4). However, the Test Report has not been provided to FDA.\nPlease evaluate the adequacy of your corrective actions related to design verification and continue to provide us information related to your ongoing corrective actions.\n3. Failure to adequately establish and maintain procedures for design change as required by 21 CFR 820.30(i).\nFor example, your firm has not implemented your procedure for design changes titled, Design Control (SOP 00003, Rev. C, effective date 02\u002F01\u002F2021 & Rev. D, effective date 11\u002F14\u002F2022) (revisions in effect when design changes were processed), which states that design changes are subject to original verification or validation tests and if no test(s) or a subset is planned, a justification is required. Specifically, your firm has not evaluated the impact changes may have to original verification or validation tests or provided a justification if no test(s) or a subset is required. Design changes were made to update the specification for your 072 Cather, Nitinol Tip (b)(4) (under ECO 1142) and to update the (b)(4) specification (under ECO 1360) (b)(4) acceptability range (b)(4). No assessment was documented of the potential impact the changes could have on completed verification and\u002For validation tests.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s reevaluation of ECO 1360 states that the firm’s risk management document, RM 00951, Design FMEA, 072 Aspiration System, was updated in ECO 1300 to capture the new risk identified with SA 00570 (b)(4). It further states that testing was performed via (b)(4). Your firm determined that verification and\u002For validation testing was not required. This assessment is inadequate. Testing should be documented and performed according to a defined protocol.\nPlease evaluate the adequacy of your corrective actions related to design changes and continue to provide us information related to your ongoing corrective actions.\n4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\nFor example, your firm has not adequately implemented your complaint procedure, Complaint Handling and Customer Feedback (SOP 00148, Rev. M, effective date 02\u002F27\u002F2024), which requires returned product analysis to be completed within 30 days after receiving the product from the field. Specifically,\nCN 0251 was opened to document a complaint reporting resistance was felt while the Hippo 072 Aspiration Catheter was inside an access catheter. The associated complaint product was received by your firm on 06\u002F12\u002F2024 under RMA0494 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\nCN 0252 was opened to document a complaint reporting stretching on the distal portion of the 072 Aspiration Tubing. The associated complaint product was received by your firm on 06\u002F27\u002F2024 under RMA0493 and logged in RMA log. As of 08\u002F02\u002F2024 the complaint product has not been investigated.\nWe reviewed your firm’s response and conclude that it is not adequate. Removing the 30-day timeframe for completing the returned product analysis may impact your firm’s assessment of complaints that are determined to be malfunctions and thus your firm’s adherence to reporting timeframes required as part of the Medical Device Reporting (MDR) Regulation (see 21 CFR Part 803). Your firm should provide a risk-based justification for the removal of the requirement and evaluate complaints to determine if any unreported MDRs were found.\n5. Failure to adequately establish and maintain procedures for document control as required by 21 CFR 820.40.\nFor example, your firm did not adequately implement your document control procedures as outlined in (b)(4) (SOP 00002, Rev. R, effective date 05\u002F24\u002F2024 (current revision), Rev. P, effective date 02\u002F02\u002F2024, and Rev. N, effective date 07\u002F14\u002F2023. Section 6.1 of your procedure titled (b)(4) (SOP 00460, Rev, A, effective date 9\u002F14\u002F2020) (b)(4). Specifically, the following promotional material for the 072 Aspiration System (Hippo) was not developed and approved per the firm’s document control procedures:\nA video clip depicting the tip of the Hippo aspiration catheter flaring out\nA video clip referring the to the Hippo aspiration catheter tip as adaptive, depicting the tip of the Hippo aspiration catheter flaring out, and referencing R&D Aspiration Grip Force data\nA press release announcing the clearance of the Hippo 072 Aspiration System that describes the aspiration tip as adaptive\nWe reviewed your firm’s response and cannot determine the adequacy at this time. Your firm extended the target completion date to 11\u002F25\u002F2025, for compiling of a list of marketing\u002F promotional content for their Armadillo and Walrus devices and evaluating if product claims were found. (b)(4); therefore, we request that you continue to provide information related to the (b)(4).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via e-mail to: Jessica Mu, Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Refer to the Unique Identification Number, CMS # 699244, when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov or 619-941-3763.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Q’Apel Medical, Inc.","qapel-medical-inc-699244-02052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fqapel-medical-inc-699244-02052025","2026-10-26T08:09:46.009809+00:00","2025-03-11","699244","Jodie C. Fam","2026-08-19T16:59:01.909+00:00","2025-02-05",{"id":156,"raw":157,"subject":161,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":166,"fei_number":20,"letter_url":167,"updated_at":168,"action_type":23,"case_status":24,"posted_date":169,"marcs_cms_no":170,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":171,"body_fetched_at":172,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":173,"medical_device_id":20,"response_letter_date":20},3235,[158,159,160,37,161,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-26T04:00:00Z\">07\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021\">Lexion Medical LLC\u003C\u002Fa>","Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick Spearman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lexion Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Atwater Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pspearman@lexionmedical.com\"> pspearman@lexionmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 26, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Patrick Spearman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&amp;feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AP 50\u002F30 Insufflator and Insuflow Port\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\u003C\u002Fp>\n\n\u003Cp>For example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\u003C\u002Fp>\n\n\u003Cp>• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\u003Cbr>\n “Less hypothermia”\u003Cbr>\n “Less peritoneal damage”\u003Cbr>\n “Less postoperative pain”\u003Cbr>\n “Decreased amount of pain medication”\u003Cbr>\n “Shortened recovery room stay”\u003Cbr>\n “Less tissue dessication”\u003Cbr>\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\u003C\u002Fp>\n\n\u003Cp>There are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pneuview XE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\u003C\u002Fp>\n\n\u003Cp>• “Eliminate \u003Cem>all\u003C\u002Fem> plume, gases, and particles” [emphasis added]\u003Cbr>\n• “…eliminating \u003Cem>all\u003C\u002Fem> harmful contaminants associated with combustion, including viral particles” [emphasis added]\u003Cbr>\n• “actively evacuates and removes \u003Cem>all \u003C\u002Fem>smoke plume including hazardous gas” [emphasis added]\u003Cbr>\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\u003C\u002Fp>\n\n\u003Cp>The cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\u003Cbr>\n\u003Cbr>\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\u003C\u002Fp>\n\n\u003Cp>• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\u003Cbr>\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\u003Cbr>\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\u003C\u002Fp>\n\n\u003Cp>• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\u003Cbr>\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\u003Cbr>\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\u003Cbr>\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\u003Cbr>\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\u003Cbr>\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\u003C\u002Fp>\n\n\u003Cp>Taken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>In combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC\u003Cbr>\nShelly Amann, Owner\u003Cbr>\nLexion Medical LLC\u003Cbr>\n545 Atwater Circle\u003Cbr>\nSaint Paul, MN 55103\u003Cbr>\nsamann@lexionmedical.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. \u003Cem>J Robot Surg\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick Spearman\n\nRecipient Title\n\nOwner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nUnited States\n\npspearman@lexionmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJuly 26, 2021\n\nRE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Patrick Spearman:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nAP 50\u002F30 Insufflator and Insuflow Port\n\nThe AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\n\nFor example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\n\n• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\n\n “Less hypothermia”\n\n “Less peritoneal damage”\n\n “Less postoperative pain”\n\n “Decreased amount of pain medication”\n\n “Shortened recovery room stay”\n\n “Less tissue dessication”\n\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\n\nThere are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\n\nPneuview XE\n\nThe Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\n\n• “Eliminate all plume, gases, and particles” [emphasis added]\n\n• “…eliminating all harmful contaminants associated with combustion, including viral particles” [emphasis added]\n\n• “actively evacuates and removes all smoke plume including hazardous gas” [emphasis added]\n\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\n\nThe cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\n\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\n\n• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\n\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”2 (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\n\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\n\nWe are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\n\nAdditionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-193 in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\n\n• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\n\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\n\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\n\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\n\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\n\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\n\nTaken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\n\nIn combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nNote, there are two response time frames specified. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\n\nYour firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\n\nPlease refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\n\nFinally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC\n\nShelly Amann, Owner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nsamann@lexionmedical.com\n\n______________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. J Robot Surg.\n\n3 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n4 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Lexion Medical LLC","lexion-medical-llc-613588-07262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021","2026-10-26T08:09:14.12601+00:00","2021-08-03","613588","Patrick Spearman","2026-08-20T02:44:07.37+00:00","2021-07-26",{"id":175,"raw":176,"subject":180,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":43,"fei_number":20,"letter_url":185,"updated_at":186,"action_type":23,"case_status":24,"posted_date":187,"marcs_cms_no":188,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":189,"delivery_method":135,"recipient_title":20,"reference_number":20,"action_taken_date":190,"medical_device_id":20,"response_letter_date":20},472,[177,178,179,11,180,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","2026-08-19T14:27:25.954+00:00","2025-11-13",{"id":192,"raw":193,"subject":38,"body_html":197,"body_text":198,"firm_name":199,"letter_id":200,"created_at":43,"fei_number":20,"letter_url":201,"updated_at":202,"action_type":23,"case_status":24,"posted_date":203,"marcs_cms_no":204,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":205,"body_fetched_at":206,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":207,"medical_device_id":20,"response_letter_date":20},266,[194,195,196,37,38,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-03T04:00:00Z\">09\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025\">Avertix Medical, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy P. Moran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Avertix Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>40 Christopher Way, Ste 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eatontown\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07724\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tmoran@avertix.com\"> tmoran@avertix.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 711080\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 3, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Moran:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\u003C\u002Fp>\u003Cp>a. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\u003C\u002Fp>\u003Cp>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\u003C\u002Fp>\u003Cp>Additionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\u003C\u002Fp>\u003Cp>iv. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\u003C\u002Fp>\u003Cp>v. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\u003C\u002Fp>\u003Cp>vi. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\u003C\u002Fp>\u003Cp>The above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm’s \u003Cem>Complaint Procedure\u003C\u002Fem>, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\u003C\u002Fp>\u003Cp>i. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\u003C\u002Fp>\u003Cp>ii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\u003C\u002Fp>\u003Cp>iii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\u003C\u002Fp>\u003Cp>iv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\u003C\u002Fp>\u003Cp>c. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\u003C\u002Fp>\u003Cp>Specifically, Section 5.1.4 of your \u003Cem>Complaint Procedure\u003C\u002Fem> requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “\u003Cem>Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “\u003Cem>Review for Closure\u003C\u002Fem>” section of the complaint records lists “\u003Cem>no investigation needed\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm also promised to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, your \u003Cem>Nonconformance Material Procedure\u003C\u002Fem>, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) on the EXD-001 Battery, 10 Packs (p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your response promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as well as plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All activities are captured in CAPA 00017 and all work is promised by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your \u003Cem>Risk Management Procedure\u003C\u002Fem>, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\u003C\u002Fp>\u003Cp>a. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of \u003Cstrong>(b)(4)\u003C\u002Fstrong> IMDs implanted as of February 25, 2025. The observed rate of infection is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>Guardian System Risk Assessment\u003C\u002Fem> – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. The risk was not reassessed.\u003C\u002Fp>\u003Cp>b. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In your device risk file, \u003Cem>IMD AMSG3-E Hardware FMECA Report – P16\u003C\u002Fem>, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> which has a \u003Cstrong>(b)(4)\u003C\u002Fstrong> planned due date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\u003C\u002Fp>\u003Cp>a. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\u003C\u002Fp>\u003Cp>b. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\u003C\u002Fp>\u003Cp>Review of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\u003C\u002Fp>\u003Cp>For example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2021 or earlier). The decision to \u003Cstrong>(b)(4)\u003C\u002Fstrong> remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response does not address if other CAPAs will be reviewed to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Several of the items promised by your firm continue to be in-progress (including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\u003C\u002Fp>\u003Cp>For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process since the 2022 requalification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003), has not been fully implemented. For example:\u003C\u002Fp>\u003Cp>a. Your firm’s \u003Cem>Supplier Management Procedure\u003C\u002Fem> (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> to Avertix. Your QA\u002FQC manager stated these \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not completed.\u003C\u002Fp>\u003Cp>b. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\u003C\u002Fp>\u003Cp>Your firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\u003C\u002Fp>\u003Cp>However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Specifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTimothy P. Moran\n\nRecipient Title\n\nPresident and CEO\n\nAvertix Medical, Inc.\n\n40 Christopher Way, Ste 201\n\nEatontown, NJ 07724\n\nUnited States\n\ntmoran@avertix.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 711080\nSeptember 3, 2025\nDear Mr. Moran:\nDuring an inspection of your firm located in Eatontown, NJ from February 19, 2025, through March 11, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures The Guardian System, an implantable coronary syndrome event detector. The Guardian System consists of three main system components: an implantable device used to monitor a patient’s electrogram (IMD); a hand-held telemetry device that provides alarms and alerts and interfaces between the IMD and programmer (EXD); and a programmer utilized by healthcare professionals to program the IMD and alarm\u002Falert settings and retrieve and review IMD data (Programmer). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from David Keenan, Chief Technology Officer, dated March 31, 2025, and June 20, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to maintain complaint files; and failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, the firm’s procedure, Complaint Procedure, #1716-002, Rev Q (dated February 25, 2022) to Rev R (dated April 11, 2022) has not been adequately established in that:\na. Your firm failed to adequately maintain complaint files, as required by 21 CFR 820.198(a).\nSpecifically, section 5.1.2 of your complaint procedure requires all employees to report any product complaint or feedback from the field. Section 5.1.3 of the complaint procedure covers the review of “ISSUES” to disposition them as a “COMPLAINT” or “REJCT\u002FNo ACTION REQUIRED”. The FDA investigator identified 11 issues which meet the definition of a complaint and were not dispositioned as a complaint as required by your procedure. For example:\ni. (b)(4), reported on November 6, 2023, listing the patient effect description as “Guardian Device was removed from the patient due to a recurrent pocket infection post implant.”\nii. (b)(4), reported on March 4, 2022, listed the programmer battery connector broke when trying to remove the battery.\niii. (b)(4), reported on September 6, 2023, listed the USB Drive for Programmer was not connected and required formatting each time to use.\nAdditionally, six of eleven “nonconforming material reports” (NCMRs) reviewed during the inspection that met the definition of complaints were not considered complaints and as such were handled according to your nonconforming material process. For example:\niv. (b)(4), created April 30, 2024, states that a Programmer (PROG-003) was returned from the field due to issues with the battery charging indicator light.\nv. (b)(4), created September 6, 2023, states a USB flash drive was not functioning properly in the field and was returned.\nvi. (b)(4), created November 22, 2022, states that a field clinical engineer reported that a Programmer Battery was damaged while being inserted into the Programmer.\nThe above “issues” and “nonconforming product reports” were not evaluated for MDR reportability and were not reviewed to determine if an investigation is necessary, since they were not considered complaints.\nb. Your firm failed to adequately establish and maintain procedures to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1).\nSpecifically, your firm’s Complaint Procedure, #1716-002, does not include a requirement for timely and uniform complaint handling. For example, the following complaints were entered as issues and were not escalated to complaints in a timely manner:\ni. Complaint-00077: On July 17, 2024, your firm became aware of a reported issue where the physician was unable to retrieve data from the IMD implant. The complaint record was not opened until September 5, 2024 (50 days after becoming aware).\nii. Complaint-00066: On February 13, 2024, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until March 28, 2024 (44 days after becoming aware).\niii. Complaint-00059: On November 30, 2023, your firm became aware of a reported “flat line IMD” event. The complaint record was not opened until January 5, 2024 (36 days after becoming aware).\niv. Complaint-00039: On October 28, 2022, your firm became aware of an IMD explant due to an infection. The complaint record was not opened until December 1, 2022 (34 days after becoming aware).\nc. Your firm failed to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820 820.198(c).\nSpecifically, Section 5.1.4 of your Complaint Procedure requires investigation of complaints. Your firm failed to adequately review, evaluate, and investigate the following complaints that reported patient infection and subsequent explant of the implantable cardiac monitoring device (IMD), the implantable portion of The Guardian System:\ni. (b)(4), reported on February 13, 2024, that subsequently became Complaint-00066, documents the justification for not performing an investigation as: “Physician determined patient had a pocket infection and made the decision to explant and device. No investigation needed.”\nii. (b)(4), reported on October 28, 2022, that subsequently became Complaint-00039, documents the “Initiate Investigation Process” option was selected but no investigation was performed and the “Review for Closure” section of the complaint records lists “no investigation needed.”\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm states that CAPA 00015 was opened to capture all corrective and preventive work performed in relation to this observation. As part of CAPA 00015, your firm promised to (b)(4). Your firm also promised to (b)(4). However, the response does not address performing a retrospective review of all issues and nonconforming product reports to determine if other complaints exist and if investigations need to be performed. Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a).\nSpecifically, your Nonconformance Material Procedure, #1707-002, does not include a provision for the determination of the need for an investigation. For example, the following two nonconformances did not include a documented investigation or evaluation:\na. (b)(4) was created on June 27, 2024, for IMD batteries that were sent to your contract manufacturer for use in production were returned due to nonconformances (bent prongs). The disposition of the batteries was recorded as being scrapped. However, there was no investigation conducted into the cause of the bent probes and the nonconformance record does not include a rationale for not investigating.\nb. (b)(4) was created on June 7, 2023, for the EXD-001 Battery Packaging Label (p\u002Fn (b)(4)) on the EXD-001 Battery, 10 Packs (p\u002Fn (b)(4)) listing an incorrect expiration date and battery lot code in finished goods inventory. Your firm reworked the nonconforming product. However, there was no investigation conducted into the cause of the incorrect labeling and the nonconformance record does not include a rationale for not investigating.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your response promises to (b)(4) as well as plans to (b)(4). All activities are captured in CAPA 00017 and all work is promised by (b)(4). However, your response fails to address if a retrospective review of NCMRs will be conducted. Several of these promised actions (including CAPA 00017) remain in-progress with a tentative CAPA Effectiveness Verification planned due date of (b)(4).\n3. Failure to adequately establish and maintain procedures for validating the device design to include adequate risk analysis, as required by 21 CFR 820.30(g). Specifically, section 6.14 of your Risk Management Procedure, #1701-011, covers the information collection, information review, and actions related to the use of the Corrective and Preventive Action System and the Complaint System to monitor the device in the clinical and post-production phase to determine if reassessment of risks and\u002For assessment of new risks is necessary. Your firm failed to reassess the risk when estimated risks from a hazard differed from the actual risk observed in post-market CAPA and complaint data. For example:\na. Your firm has received three complaints of infection with the IMD portion of the Guardian System out of a total of (b)(4) IMDs implanted as of February 25, 2025. The observed rate of infection is (b)(4)%. In your device risk file, Guardian System Risk Assessment – P18, #0201-0200-001#P18, Rev B, dated November 13, 2023, the rate of infection was estimated to be (b)(4)%. The risk was not reassessed.\nb. Your firm has received 24 complaints of battery failure due to electrical short before the device reached its expected service life of 6 years, causing patients to opt for early explant and\u002For replacement. The observed rate of battery failure is (b)(4)%. In your device risk file, IMD AMSG3-E Hardware FMECA Report – P16, #0212-0201-001#P16, Rev A; dated February 24, 2015, the rate of battery failure was estimated to be (b)(4)%. Further, your firm initiated CAPA-00012 in response to the battery failures. The “Process Impacts” section of this CAPA indicates that no updates to risk management were needed. The risk was not reassessed.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the response, your firm indicates that CAPA 00016 was opened to address any corrective and preventive work taken as result of the observation including to assess the risk associated with infection using current performance data against historical data and to address the need to perform risk reviews on a regularly scheduled basis to keep the risk data current by July 1, 2025. However, your firm did not indicate if you intend to review, and update as necessary, the risk file utilizing post-market data for items other than risk of infection. Several of the items promised by your firm continue to be in-progress, including but not limited to (b)(4) which has a (b)(4) planned due date of (b)(4).\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm failed to follow your procedure, Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, when taking corrective and preventive actions. Two examples of lack of CAPA procedure implementation are as follows:\na. Your firm failed to follow your CAPA process for a corrective action taken as a result of a consumer complaint which led to a revision made to manufacturing procedure Process Specification, PROG-004 Final Shipping Manufacturing, #0217-1200-020#P18, Rev F, dated November 19, 2024. These actions were taken outside of the CAPA system and lack a documented CAPA investigation as well as verification of implementation and effectiveness.\nb. Your firm failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). Specifically, section 5.9 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes your firm’s process for establishing verification of effectiveness plans with predetermined criteria that verify if corrective and\u002For preventive actions were effective. Additionally, section 5.10 of the Corrective and Preventive Action Procedure, #1708-001, Rev J, dated October 23, 2020, describes the process for conducting the verification of effectiveness (VOE) phase to demonstrate effectiveness.\nReview of five CAPAs closed between January 2022 and the time of the current inspection disclosed that four CAPAs (CAPA-00007, CAPA-00008, CAPA-00010, and CAPA-00014) lacked evidence that your firm verified or validated that the action taken was effective.\nFor example, CAPA-00007, was opened as a result of the previous inspection on March 15, 2022, related to a complaint involving EXD batteries having expired shelf life. Your firm implemented several corrective actions to correct the issue which were documented utilizing the complaint record (complaint number 00013) instead of through the CAPA system. CAPA-00007 was closed on March 31, 2022, without verifying the effectiveness of the correction and preventive actions taken.\nWe reviewed your firm’s responses and conclude that they are not adequate. In this response, your firm opened CAPA 00016 to document actions taken for this observation. Your firm promises to (b)(4). For the 5 CAPAs lacking VOE plans and reports, your firm asks our Agency if (b)(4) (2021 or earlier). The decision to (b)(4) remains your firm’s decision as long as it is based on a rationale you determine to be appropriate given the 21 CFR 820.100(a)(4) and your own procedural requirement to demonstrate effectiveness of a CAPA action. You are also going to (b)(4). Your response does not address if other CAPAs will be reviewed to determine if (b)(4). Several of the items promised by your firm continue to be in-progress (including but not limited to (b)(4).\n5. Failure to validate with a high degree of assurance and approve according to established procedures, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically, your firm’s Process Validation Procedure, #1705-002, Rev E, dated October 23, 2020, and Process Qualification Procedure, #1705-001, Rev F, dated October 23, 2020, were not adequately established in that both procedures fail to address sterilization validation. Your firm’s implantable cardiac monitoring device (IMD) undergoes (b)(4) sterilization. Further, the two procedures fail to document the process of requalification and revalidation (if necessary) of the sterilization cycle.\nFor example, the (b)(4) sterilization process for your firm’s IMD was last performed in June 2022 by a 3rd party in accordance with FDA-recognized standard ANSI\u002FAAMI\u002FISO 11135:2014. Your firm has not reviewed the (b)(4) sterilization process since the 2022 requalification.\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, you indicate that CAPA 00019 was opened as a result of the observation and that your firm promises to (b)(4). However, your responses do not address if your firm’s plans to revise your process validation procedures to include sterilization. Additionally, supporting evidence (including CAPA 00019) of these promised actions remain in progress with a CAPA Effectiveness Verification planned due date for CAPA 00019 of (b)(4).\n6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors, and consultants, as required by 21 CFR 820.50(a). Specifically, your Supplier Management Procedure (#1703-003), has not been fully implemented. For example:\na. Your firm’s Supplier Management Procedure (#1703-003) describes a process for supplier evaluation and acceptance using a supplier evaluation form. The Supplier Evaluation Form for the IMD battery supplier, (dated February 13, 2020), indicated your firm’s contract manufacturer would perform receiving inspections of these batteries and provide (b)(4) to Avertix. Your QA\u002FQC manager stated these (b)(4) were not completed.\nb. Your firm failed to adequately establish and maintain records of acceptable suppliers, contractors, and consultants, as required by 21 CFR 820.50(a)(3). Specifically, section 7.1.12 of Supplier Management Procedure, Rev K, states that “Quality Assurance is responsible for revising the Approved Supplier List with changes made based on acceptance\u002Frejection of potential suppliers\u002Fre-evaluated suppliers\u002Fdeactivated suppliers…” A software supplier used by your firm since 2023 to meet the requirements of the Medical Device Tracking regulation was not listed on your Approved Supplier List (Rev L, dated June 15, 2023).\nWe reviewed your firm’s responses and conclude that they are not adequate. In the responses, your firm promises and provided revisions to your Supplier Management Procedure (Document 1703-003) removing the requirement for (b)(4) for your contract manufacturer and to evidence of a new supplier evaluation for the software supplier utilized for medical device tracking by July 1, 2025. The responses do not indicate if other supplier evaluations will be evaluated and updated, as needed. Further, CAPA 00023 remains in progress with a CAPA Effectiveness Verification planned due date of December 1, 2025.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s Guardian System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, the information included for Complaint-00066, Issue-00091, and Complaint-00039 reasonably suggests that each patient sustained an injury or illness (i.e., infection) following implantation of your firm’s Guardian System. These infections constituted serious injuries within the meaning of 21 CFR 803.3(w) because they necessitated surgical intervention (i.e., explantation) to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of information that reasonably suggests that the Guardian System may have caused or contributed to a serious injury on February 13, 2024, for Complaint-00066, on November 6, 2023, for Issue-00091, and on October 28, 2022, for Complaint-00039. As such, Complaint-00066, Issue-00091, and Complaint-00039 represent MDR reportable events, as defined in 21 CFR 803.3(o)(2)(i). However, the FDA did not receive an MDR for each referenced event until April 10, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced serious injury events after the 30 calendar day reporting timeframe had elapsed. However, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\n2. Failure to report to the FDA the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included for Complaints No. 00057, 00065, 00070, 00071, 00072, 00074, 00077, 00079, 00080, 00082, 00083, and 00086, reasonably suggests that your firm’s Guardian System malfunctioned while in use. Specifically, the device prematurely reached its end of service due to early battery depletion, meaning that it failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). Your firm initiated recall Z-1140-2025 for the referenced malfunction. A malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63585 (Dec. 11, 1995) (referring to section 519(f), which has since been redesignated as section 519(g)). As such, the referenced complaints represent MDR reportable events, as defined under 21 CFR 803.3(o)(2)(ii).\nYour firm became aware of information on the following dates that reasonably suggests that the Guardian System had malfunctioned and this device or a similar device your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur: October 10, 2023, for Complaint No. 00057; February 26, 2024, for 00065; May 28, 2024, for 00070; May 14, 2024, for 00071; May 5, 2024, for 00072; May 14, 2024, for 00074; July 17, 2024, for 00077; August 29, 2024, for 00079; August 21, 2024, for 00080; November 19, 2024, for 0008; November 19, 2024, for 00083; and December 3, 2024, for 00086. Your firm submitted a report for each event using the MedWatch Online Voluntary Reporting Form. Specifically, MW5149541 (Complaint No. 00057), MW5153561 (Complaint No. 00065), MW5159171 (Complaint No. 00070), MW5159172 (Complaint No.00071), MW5159173 (Complaint No. 00072), MW5159805 (Complaint No. 00074), MW5160629 (Complaint No. 00077), MW5160632 (Complaint No. 00079), MW5160633 (Complaint No. 00080), MW5164478 (Complaint No. 00082), MW5164476 (Complaint No. 00083), and MW5164481 (Complaint No. 00086). The submission of reports using the voluntary MedWatch Online Voluntary Reporting Form does not fulfill reporting obligations arising under 21 CFR Part 803. An electronic submission of a mandatory report from a manufacturer must contain the information from the applicable blocks of Form FDA 3500A. All medical device reports must be submitted within the required timeframes. However, the FDA did not receive the corresponding MDRs until April 14, 2025, which exceeded the required 30 calendar day reporting timeframe.\nThe adequacy of your firm’s responses cannot be determined at this time. We acknowledge that the FDA received the manufacturer reports, submitted using the electronic equivalent of Form 3500A, for the referenced malfunction events based on your firm’s retrospective review on April 14, 2025, after the 30 calendar day reporting timeframe had elapsed.\nHowever, although the response referenced the updated MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, as part of its correction action for the late reporting issue, a copy of the updated MDR procedure was not included.\nIn addition, the inspection revealed that your firm failed to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, your firm presented the document titled “Medical Device Vigilance Procedures,” Document No. 1716-005, Rev. F, dated June 25, 2024, as its MDR procedure. Upon review, we conclude that the MDR procedure does not develop, maintain, and implement written MDR procedures for internal systems that provide for timely transmission of complete medical device reports to FDA, as required by 21 CFR 803.17(a)(3). Specifically, the procedure 1716-005, Rev. F does not include instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that FDA can process, review, and archive. As a manufacturer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with 21 CFR 803.12(a) and 803.20, unless granted an exemption under 21 CFR 803.19.\nThe adequacy of your firm’s responses cannot be determined at this time. While your response included a copy of the updated Complaint Procedure, Document No.1716-002, and staff training records, it referenced an update to the MDR procedure “Medical Device Vigilance Procedures,” Document No. 1716-005, without including a copy. Without the referenced document, we cannot fully assess the adequacy of the response.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s Guardian System Model AMSG3‐E IMD implant devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals was promulgated under section 519 of the Act, among other provisions. Violations include, but are not limited to, the following:\nFailure to submit to the FDA within 10 working days of initiating a correction or removal a report required by 21 CFR 806.10.\nSpecifically, on September 18, 2023, Avertix Medical, Inc., delivered a letter to physicians who have patients implanted with a Model AMSG3‐E IMD manufactured during the period when a contamination issue was occurring on the battery production line. This issue led to premature battery depletion in the Guardian System implants, which can result in failure to monitor and earlier‐than‐expected implant replacement surgery. The letter recommends reducing the interval of regular follow-up visits and reinforcing the patient training. FDA determined that shorter device implant life leading to sooner than expected replacement surgery may present a risk to health. This action constitutes a medical device correction or removal initiated to reduce a risk to health posed by the device or remedy a violation of the Act caused by the device which may present a risk to health under 21 CFR 806.10(a). Accordingly, you were required to submit a Report of Correction or Removal to FDA within 10 working days of initiation, under 21 CFR 806.10(b). You submitted a Medical Device Report of Correction or Removal to FDA for this action on December 11, 2024.\nWe reviewed your firm’s responses and conclude that they are not adequate. The responses do not contain evidence that your firm’s procedures will result in compliance with the medical device correction and removal reporting requirements in 21 CFR 806. CAPA 00020 states that management failed to recognize that it needed to submit a Report of Correction or Removal within 10 working days of initiation. Your corrective action was retraining personnel in two procedures, Complaint Procedure (1716-002) and Vigilance Procedure (1716-005). You stated that your Quality Management System (QMS) procedure specifies that recalls or corrections must be reported within 10 days. However, your responses did not include a new revision of 1716-005 nor procedure 1716-004, PRODUCT RECALLS, CORRECTIONS AND REMOVALS. Procedure 1716-004 Rev F, collected in the inspection, notes that the Recall Coordinator is responsible for communicating with regulatory agencies within defined reporting times as per the Vigilance procedure. The procedure titled MEDICAL DEVICE VIGILANCE PROCEDURES, 1716-005 Rev F, collected during the inspection, does not describe Reports of Corrections or Removals, required by 21 CFR 806. Therefore, training personnel on 1716-005 will not help personnel know the timeframe for reporting a Medical Device Correction or Removal to FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 711080” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Avertix Medical, Inc.","avertix-medical-inc-711080-09032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favertix-medical-inc-711080-09032025","2026-10-26T08:07:59.649711+00:00","2026-03-17","711080","Timothy P. Moran","2026-08-19T04:50:38.23+00:00","2025-09-03",{"id":209,"raw":210,"subject":215,"body_html":216,"body_text":217,"firm_name":218,"letter_id":219,"created_at":43,"fei_number":20,"letter_url":220,"updated_at":221,"action_type":23,"case_status":24,"posted_date":222,"marcs_cms_no":223,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":224,"body_fetched_at":225,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":226,"medical_device_id":20,"response_letter_date":20},63,[211,212,213,37,214,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","2026-05-20",{"id":228,"raw":229,"subject":215,"body_html":233,"body_text":234,"firm_name":235,"letter_id":236,"created_at":107,"fei_number":20,"letter_url":237,"updated_at":238,"action_type":23,"case_status":24,"posted_date":239,"marcs_cms_no":240,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":241,"body_fetched_at":242,"delivery_method":243,"recipient_title":20,"reference_number":20,"action_taken_date":244,"medical_device_id":20,"response_letter_date":20},954,[230,231,232,37,215,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","VIA UNITED PARCEL SERVICE","2025-04-04",{"id":246,"raw":247,"subject":143,"body_html":252,"body_text":253,"firm_name":254,"letter_id":255,"created_at":65,"fei_number":20,"letter_url":256,"updated_at":257,"action_type":23,"case_status":258,"posted_date":259,"marcs_cms_no":260,"product_type":48,"closeout_date":261,"issuing_office":37,"recipient_name":262,"body_fetched_at":263,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":264,"medical_device_id":20,"response_letter_date":20},2483,[248,249,250,37,143,13,251,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","Closed Out","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":266,"raw":267,"subject":123,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":128,"fei_number":20,"letter_url":275,"updated_at":276,"action_type":23,"case_status":24,"posted_date":277,"marcs_cms_no":278,"product_type":48,"closeout_date":20,"issuing_office":37,"recipient_name":279,"body_fetched_at":280,"delivery_method":135,"recipient_title":20,"reference_number":20,"action_taken_date":281,"medical_device_id":20,"response_letter_date":20},1199,[268,269,270,37,123,13,13,13],"\u003Ctime datetime=\"2024-10-29T04:00:00Z\">10\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-22T05:00:00Z\">11\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fargon-medical-productions-vertrieb-gesellschaft-mbh-co-694763-11222024\">Argon Medical Productions &amp; Vertrieb Gesellschaft MBH &amp; CO\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard Donaca\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Argon Medical Productions &amp; Vertrieb Gesellschaft MBH &amp; CO\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Franz Kirsten Str. 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bingen Am-Rhein\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>55411\u003C\u002Fspan> \u003Cspan>Rhineland-Palatinate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:r.donaca@argon-group.de\"> r.donaca@argon-group.de \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 22, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Donaca:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Bingen am-Rhein, Germany on 7\u002F29\u002F2024 through 7\u002F31\u002F2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures K3Pro and K3Pro Rapid Implant (Konus Dental Implant System), K3Pro Konus Additional Abutments and Implants, and K3Pro Konus New Abutments and Implants. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Marcel Kumpa-Management Representative dated 08\u002F21\u002F2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or package to meet any of its specification unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). For example:\u003C\u002Fp>\u003Cp>Complaints involving potential device failures, such as the failure of dental implants to osseointegrate, were not investigated as required. During the inspection, the investigator identified Complaint number 23.058, titled \"Osseointegration guarantee,\" as lacking both an investigation and a reference to a prior investigation.\u003C\u002Fp>\u003Cp>According to your firm’s AA_005_complaint processing procedure, all complaints must be investigated through a technical assessment, as outlined on page 4. However, your firm justified its approach by stating that it does not investigate osseointegration complaints due to the complexity of patient-specific factors, such as smoking or diabetes, which can influence the outcome.\u003C\u002Fp>\u003Cp>By failing to conduct or document the required technical assessment, your firm is in violation of your own complaint processing procedure, which does not provide any additional instruction on complaints that do not require an investigation. Also, your firm’s records do not make reference to any investigation to similar complaints to justify why a duplicative investigation for the aforementioned complaint is not necessary.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated 08\u002F21\u002F2024 and conclude that it is not adequate. Your firm determined that complaints involving nonconformities are considered low risk and are not investigated. Your firm explained that the root causes of these complaints are managed as part of your osseointegration guarantee, with the complaints being processed as returns rather than being investigated. As part of your proposed corrective action, your firm plans to revise your process instructions, work instructions, and forms for handling complaints. In your response, your firm committed to treating osseointegration cases as separate complaints, ensuring that any cases involving serious patient injury will be investigated and reported in accordance with FDA's Medical Device Reporting (MDR) requirements under 21 CFR 803. Your firm also proposed to review 2023 and 2024 complaint statistics to evaluate whether there is an obligation to report certain cases. Your firm's response does address the need for a retrospective review of previous complaints and product returns to assess whether any past cases should have been treated as quality complaints or reported under MDR requirements.\u003C\u002Fp>\u003Cp>Additionally, your firm's response did not include any documentation or evidence of the proposed corrective actions, as these measures are still in progress. Without evidence or timelines for completion, it is difficult to assess the adequacy and effectiveness of the planned corrections.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s K3Pro dental implants are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm acknowledged the procedure Post Market Surveillance procedure A002 as its written MDR procedure, and agreed with the investigator that the procedure have the following deficiencies:\u003C\u002Fp>\u003Cp>a) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803.\u003C\u002Fp>\u003Cp>b) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\u003C\u002Fp>\u003Cp>Additionally, as of September 13, 2023, your firm had not completed its load test and guidance compliance submission for electronic Medical Device Reporting (eMDR). We recommend your firm follow the instructions provided at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program under “Low Volume Enrollment Process” to obtain its WebTrader production account. A tutorial video is also available at https:\u002F\u002Fyoutu.be\u002FEdKy5wl8F18 to guide low-volume submissions for eMDR. Furthermore, the MDR procedure is written in a foreign language. Without an English translation, we are unable to fully assess your firm’s MDR procedure.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated August 21, 2024, cannot be determined at this time. In the response, your firm referenced the 21 CFR 803 requirements and states that it plans to revise it adverse event reporting work instructions AA_002 to incorporate these requirements and conduct staff training. However, your firm has not provided English-translated documents for the revised MDR procedure, as the revision is still in progress.\u003C\u002Fp>\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>For example, during the inspection, your firm acknowledged that Complaints 23.058, 23.060, and 23.062 describe events where patients experienced osseointegration failure after using your firm’s K3Pro dental implants. We believe osseointegration failure necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm also acknowledge that there is no information indicating that the device might not be a contributing factor leading to the osseointegration failure. Therefore, the referenced events meet the criteria for MDR reportable serious injury, as defined in 21 CFR 803.3. Your firm became aware of the events for Complaint 23.058 on April 3, 2023, 23.060 on April 17, 2023, and 23.062 on April 19, 2023. However, your firm has not submitted a serious injury MDR for each of these adverse events.\u003C\u002Fp>\u003Cp>Your firm’s response dated August 21, 2024, cannot be determined at this time. In the response, your firm states that it continuously monitors complaint statistics related to osseointegration failure and highlighted that osseointegration is highly patient-dependent, influenced by various factors such as pre-existing conditions, oral hygiene, smoking, and diet. Your firm also promised to conduct a retrospective review of complaints from the past two years to assess reportability. However, your firm has not provided any documents or evidence indicating the completion of this retrospective review.\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the K3Pro Kronus Dental implant devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for the K3Pro Kronus Dental implant devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the K3Pro Rapid (Ref 40009K3PRO.R), K3Pro XP-Line (Ref BSP.XP 35020\u002F3), and K3Pro S-line (Ref 45011K3PRO.S) (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of K3Pro XP-Line (Ref BSP.XP 35020\u002F3) (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, the K3Pro XP-Line (Ref BSP.XP 35020\u002F3) devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Argon Medical Productions &amp; Vertrieb Gesellschaft MBH &amp; CO is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #694763 when replying. If you have any questions about the contents of this letter, please contact: Andrew I. Steen at 301-796-6284.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>Director\u003Cbr>OHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>Respiratory, ENT and Dental Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Celline Lakus\u003Cbr>Argon Dental USA LLC\u003Cbr>1000 Corporate Dr\u003Cbr>Marshfield, WI US 54449\u003Cbr>Phone: 715 8981434 ext\u003Cbr>Fax: 715 3874100\u003Cbr>Email: cellinel@argondentalusa.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Richard Donaca\n\nRecipient Title\n\nCEO\n\nArgon Medical Productions & Vertrieb Gesellschaft MBH & CO\n\nFranz Kirsten Str. 1\n\nBingen Am-Rhein\n\n55411 Rhineland-Palatinate\n\nGermany\n\nr.donaca@argon-group.de\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nOctober 22, 2024\nDear Mr. Donaca:\nDuring an inspection of your firm located in Bingen am-Rhein, Germany on 7\u002F29\u002F2024 through 7\u002F31\u002F2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures K3Pro and K3Pro Rapid Implant (Konus Dental Implant System), K3Pro Konus Additional Abutments and Implants, and K3Pro Konus New Abutments and Implants. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Marcel Kumpa-Management Representative dated 08\u002F21\u002F2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or package to meet any of its specification unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). For example:\nComplaints involving potential device failures, such as the failure of dental implants to osseointegrate, were not investigated as required. During the inspection, the investigator identified Complaint number 23.058, titled \"Osseointegration guarantee,\" as lacking both an investigation and a reference to a prior investigation.\nAccording to your firm’s AA_005_complaint processing procedure, all complaints must be investigated through a technical assessment, as outlined on page 4. However, your firm justified its approach by stating that it does not investigate osseointegration complaints due to the complexity of patient-specific factors, such as smoking or diabetes, which can influence the outcome.\nBy failing to conduct or document the required technical assessment, your firm is in violation of your own complaint processing procedure, which does not provide any additional instruction on complaints that do not require an investigation. Also, your firm’s records do not make reference to any investigation to similar complaints to justify why a duplicative investigation for the aforementioned complaint is not necessary.\nWe reviewed your firm’s response dated 08\u002F21\u002F2024 and conclude that it is not adequate. Your firm determined that complaints involving nonconformities are considered low risk and are not investigated. Your firm explained that the root causes of these complaints are managed as part of your osseointegration guarantee, with the complaints being processed as returns rather than being investigated. As part of your proposed corrective action, your firm plans to revise your process instructions, work instructions, and forms for handling complaints. In your response, your firm committed to treating osseointegration cases as separate complaints, ensuring that any cases involving serious patient injury will be investigated and reported in accordance with FDA's Medical Device Reporting (MDR) requirements under 21 CFR 803. Your firm also proposed to review 2023 and 2024 complaint statistics to evaluate whether there is an obligation to report certain cases. Your firm's response does address the need for a retrospective review of previous complaints and product returns to assess whether any past cases should have been treated as quality complaints or reported under MDR requirements.\nAdditionally, your firm's response did not include any documentation or evidence of the proposed corrective actions, as these measures are still in progress. Without evidence or timelines for completion, it is difficult to assess the adequacy and effectiveness of the planned corrections.\nOur inspection also revealed that your firm’s K3Pro dental implants are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm acknowledged the procedure Post Market Surveillance procedure A002 as its written MDR procedure, and agreed with the investigator that the procedure have the following deficiencies:\na) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803.\nb) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).\nAdditionally, as of September 13, 2023, your firm had not completed its load test and guidance compliance submission for electronic Medical Device Reporting (eMDR). We recommend your firm follow the instructions provided at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program under “Low Volume Enrollment Process” to obtain its WebTrader production account. A tutorial video is also available at https:\u002F\u002Fyoutu.be\u002FEdKy5wl8F18 to guide low-volume submissions for eMDR. Furthermore, the MDR procedure is written in a foreign language. Without an English translation, we are unable to fully assess your firm’s MDR procedure.\nThe adequacy of your firm’s response dated August 21, 2024, cannot be determined at this time. In the response, your firm referenced the 21 CFR 803 requirements and states that it plans to revise it adverse event reporting work instructions AA_002 to incorporate these requirements and conduct staff training. However, your firm has not provided English-translated documents for the revised MDR procedure, as the revision is still in progress.\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nFor example, during the inspection, your firm acknowledged that Complaints 23.058, 23.060, and 23.062 describe events where patients experienced osseointegration failure after using your firm’s K3Pro dental implants. We believe osseointegration failure necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm also acknowledge that there is no information indicating that the device might not be a contributing factor leading to the osseointegration failure. Therefore, the referenced events meet the criteria for MDR reportable serious injury, as defined in 21 CFR 803.3. Your firm became aware of the events for Complaint 23.058 on April 3, 2023, 23.060 on April 17, 2023, and 23.062 on April 19, 2023. However, your firm has not submitted a serious injury MDR for each of these adverse events.\nYour firm’s response dated August 21, 2024, cannot be determined at this time. In the response, your firm states that it continuously monitors complaint statistics related to osseointegration failure and highlighted that osseointegration is highly patient-dependent, influenced by various factors such as pre-existing conditions, oral hygiene, smoking, and diet. Your firm also promised to conduct a retrospective review of complaints from the past two years to assess reportability. However, your firm has not provided any documents or evidence indicating the completion of this retrospective review.\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the K3Pro Kronus Dental implant devices do not bear such a UDI.\nSpecifically, the labels for the K3Pro Kronus Dental implant devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the K3Pro Rapid (Ref 40009K3PRO.R), K3Pro XP-Line (Ref BSP.XP 35020\u002F3), and K3Pro S-line (Ref 45011K3PRO.S) (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of K3Pro XP-Line (Ref BSP.XP 35020\u002F3) (see 21 CFR 801.40(a)(2)).\nIn addition, the K3Pro XP-Line (Ref BSP.XP 35020\u002F3) devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Argon Medical Productions & Vertrieb Gesellschaft MBH & CO is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #694763 when replying. If you have any questions about the contents of this letter, please contact: Andrew I. Steen at 301-796-6284.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMalvina B. Eydelman, M.D.\nDirector\nOHT1: Office of Ophthalmic, Anesthesia,\nRespiratory, ENT and Dental Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nCelline Lakus\nArgon Dental USA LLC\n1000 Corporate Dr\nMarshfield, WI US 54449\nPhone: 715 8981434 ext\nFax: 715 3874100\nEmail: cellinel@argondentalusa.com","Argon Medical Productions & Vertrieb Gesellschaft MBH & CO","argon-medical-productions-vertrieb-gesellschaft-mbh-co-694763-11222024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fargon-medical-productions-vertrieb-gesellschaft-mbh-co-694763-11222024","2026-10-26T08:07:57.419973+00:00","2024-10-29","694763","Mr. Richard Donaca","2026-08-19T21:17:06.346+00:00","2024-11-22",14,{"510k":284,"classification":285,"enforcement":286,"event":287,"event_backfill":288,"pma":289,"warning_letter":290},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]